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ABSTRACT 
 
 
 
Introduction. Neonatal jaundice is a common and benign condition usually resolved 
during the first week of life. Neonates with very high level of unconjugated bilirubin (UCB), 
with an increase of the free bilirubin (Bf), may develop encephalopathy, with different grade 
of severity. Typical symptoms include motor disorder, auditory dysfunction, memory and 
learning deficits, reflecting selective damage respectively for cerebellum and basal ganglia, 
inferior colliculus, and hippocampus. Several studies reported that bilirubin may activate signal 
cascades that culminate to cell survival or death, as well as modulation of mRNA expression 
of genes involved in. Histone acetylation, an epigenetic mechanism responsible for the gene 
expression regulation via opening/closing of the chromatin, was never investigated in bilirubin-
induced central nervous system (CNS) damage until now. The involvement of histone 
acetylation in common and rare neuropathologies was widely described, and also the potential 
neuroprotective action of drugs that regulate this epigenetic process. 
Aims. By the use of the animal model for hyperbilirubinemia (Gunn rat), we purpose to 
investigate the modulation of the acetyl-histone H3 (lys14) (H3K14ac) in five brain regions 
(Cortex: Cx; Cerebellum: Cll; Superior Colliculi: SC; Inferior Colliculi: IC; Hippocampus: 
Hip) of hyperbilirubinemic animals (jj) vs. non hyperbilirubinemic littermates at four post natal 
ages (P2, P9, P17 and old). Moreover, we would like to individuate the genes regulated by 
H3K14ac in jj cerebella vs. controls at P9 and eventually interpret the biological effects of this 
epigenetic modulation performing histological stainings. 
Results. Western blot analysis of H3K14ac level in all the brain regions and ages 
considered revealed a modulation of this protein that is region- and age-dependent. A 
significant increase of H3K14ac was observed in Cll, IC, and Hip in P9 jj animals, while a 
significant decrease was present in Cll and IC at P17 and Cx in older jj rats. ChIP-seq was 
performed in order to link the effect of hyperbilirubinemia on the H3K14ac with the genes 
controlled by this epigenetic mechanism in cerebella of P9 animals. Our data on H3K14ac in 
Cll and the fact that the cerebellar hypoplasia is the hallmark of hyperbilirubinemic Gunn rat 
supported this choice. Our results revealed that a very high number of genes regulated by 
H3K14ac was silenced in jj rats, while other few genes seemed to be activated in 
hyperbilirubinemic subjects. The gene ontology analysis showed that cellular development and 
differentiation, proliferation and migration, as well as apoptosis were the most modulated 
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biological processes in jj rats. These ChIP-Seq data were confirmed by our histological 
findings, that revealed higher cell density with reduction of the fibrillary component and a 
possible impairment of cell differentiation. 
Conclusions. This work reported for the first time the involvement of histone acetylation 
alterations in the brain of hyperbilirubinemic animals with a strong regulation of the gene 
expression. The complete panel of genes we obtained seemed to well-correlate with the 
bilirubin-induced damage that evidenced the development impairment. These data contribute 
to better understand the bio-molecular mechanisms that cause bilirubin toxicity but also might 
open to new therapeutical strategies in kernicterus, testing the neuroprotective properties of 
drugs that regulate the histone acetylation.  
  
III 
 
RIASSUNTO 
 
 
 
Introduzione. L’ittero neonatale è una condizione comune e benigna che si risolve entro 
la prima settimana di vita. Alcuni neonati possono sviluppare iperbilirubinemia con livelli 
molto elevati di bilirubina non coniugata (UCB), e un incremento di bilirubina libera (Bf) non 
legata ad albumina ed in grado di penetrare nel sistema nervoso centrale. Questi neonati 
possono sviluppare encefalopatia, caratterizzata da diversi gradi di severità. I sintomi principali 
di questa patologia comprendono disabilità motorie, disfunzioni uditive e deficit nella memoria 
e nell’apprendimento. Questi sintomi sono legati al danno selettivo che bilirubina è in grado di 
operare rispettivamente su cervelletto e gangli della base, collicoli inferiori ed ippocampo. 
Molti lavori hanno dimostrato che bilirubina è in grado di attivare diverse cascate di segnale 
che culminano in processi di sopravvivenza cellulare o morte, così come di modulare 
l’espressione dell’mRNA dei geni coinvolti in queste vie di segnale. L’acetilazione istonica, 
meccanismo direttamente coinvolto nella regolazione dell’espressione genica attraverso 
l’apertura o chiusura della cromatina, non è mai stato preso in considerazione nel danno al 
sistema nervoso centrale (CNS) indotto da bilirubina fino al momento attuale. Il coinvolgimento 
dell’acetilazione istonica in diverse patologie cerebrali, sia comuni che rare, è stato ampiamente 
descritto, insieme alla possibilità di trattare alcune sintomatologie di tali patologie attraverso 
l’azione neuroprotettiva di farmaci che regolano questo processo epigenetico. 
Obiettivi. Gli esperimenti sono stati condotti in vivo, usando l’animale modello che 
meglio rappresenta la condizione di iperbilirubinemia: il ratto Gunn. In questo lavoro il nostro 
scopo è quello di valutare la modulazione della acetilazione dell’istone H3 (lys 14) (H3K14ac) 
in cinque regioni cerebrali (Corteccia cerebrale: Cx; Cervelletto: Cll; Collicoli Superiori: SC; 
Collicoli Inferiori: IC; Ippocampo: Hip) degli animali iperbilirubinemici (jj) paragonati agli 
animali non iperbilirubinemici, considerando quattro età dopo la nascita (P2, P9, P17, adulti). 
Inoltre, vorremmo individuare i geni regolati da H3K14ac nel cervelletto degli animali 
iperbilirubinemici a 9 giorni dalla nascita, concludendo con una possibile interpretazione degli 
effetti biologici dati da bilirubina effettuando delle colorazioni istologiche. 
Risultati. L’analisi tramite Western blot dell’espressione della proteina H3K14ac in tutte 
le regioni cerebrali a tutte le età considerate ha mostrato una modulazione della stessa 
dipendente dalla regione e dall’età. Un aumento significativo della proteina è stato osservato in 
Cll, IC ed Hip nei jj a P9. D’altra parte una riduzione significativa è stata rilevata in Cll ed IC 
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a P17, mentre in Cx negli animali jj adulti. Per relazionare gli effetti dell’iperbilirubinemia sulla 
modulazione del H3K14ac con i geni controllati da questo meccanismo epigenetico è stata 
utilizzata la ChIP-seq su campioni di cervelletto di animali P9. Questa scelta è stata supportata 
dai dati su H3K14ac ottenuti nei campioni di cervelletto a questa stessa età, ma anche dal fatto 
che l’ipoplasia del cervelletto rappresenta la caratteristica principale dei ratti Gunn 
iperbilirubinemici. I nostri risultati hanno mostrato che un elevato numero di geni regolati da 
H3K14ac erano silenziati nei jj, mentre altri pochi geni sembrano essere specificatamente 
attivati nell’animale iperbilirubinemico. L’analisi di gene ontology ha mostrato essenzialmente 
alterazioni dei processi di sviluppo e differenziamento cellulare, proliferazione e migrazione, 
ma anche apoptosi. I dati di ChIP-Seq sono stati confermati anche dai risultati istologici che 
hanno rivelato un’elevata densità cellulare con riduzione della componente fibrillare, ed una 
possibile compromissione del differenziamento e della migrazione. 
Conclusioni. Questo lavoro ha riportato per la prima volta il coinvolgimento 
dell’acetilazione istonica nel cervello di animali iperbilirubinemici con una forte regolazione 
dell’espressione genica. Il quadro completo dei geni che abbiamo ottenuto sembrava correlare 
bene con il danno da bilirubina che ha evidenziato una compromissione dello sviluppo 
cerebrale. I nostri dati rappresentano un valido contributo nella migliore comprensione dei 
meccanismi biomolecolari che causano la tossicità da bilirubina, ma possono anche aprire 
nuove strade a strategie terapeutiche che vedono la possibilità di testare le proprietà 
neuroprotettive di farmaci che regolano l’acetilazione istonica.  
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1 INTRODUCTION 
 
 
1.1 BILIRUBIN 
 
Bilirubin (from Latin “bile” = bile and “ruber” = red) is a yellow pigment characterized by 
an open chain of four pyrrole-like rings (tetrapyrrole), derived from the porphyrin family of 
molecules, and it results from the enzymatic conversion of heme and hemoglobin. Despite the 
hypothesized antioxidant role of bilirubin observed in adults with mild levels of bilirubin without 
any kind of liver disease (Gilbert’s syndrome), high levels of bilirubin in newborn could 
compromise central nervous system leading to permanent disabilities or, at worst, death. 
 
1.1.1 BILIRUBIN METABOLISM 
 
Bilirubin produced in humans mostly derives from the degradation of erythrocyte 
hemoglobin in the spleen (80%), from the turnover of myoglobin, cytochromes and other 
hemoproteins (15-20%), and from the breakdown of immature red blood cells in the bone marrow 
1,2. A healthy adult human produces 250-400 mg of bilirubin per day 2. 
In the first step, heme group is broken in carbon monoxide (CO), ferrous iron (Fe2+) and 
biliverdin by the heme oxygenase-1 (HO-1) enzyme, consuming nicotinamide-adenine 
dinucleotide phosphate (NADPH) as reducing agent and three molecules of oxygen (O2). 
Subsequently, biliverdin is converted to bilirubin by the cytosolic biliverdin reductase enzyme 
(BVR), in the presence of NADPH 3,4. 
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Figure 1-1. Heme degradation and bilirubin production.  
Hemoglobin is converted to biliverdin by heme oxygenase. Subsequent conversion of biliverdin in unconjugated bilirubin by 
biliverdin reductase. Unconjugated bilirubin is transformed in conjugated bilirubin by UDP-glucuronosyl transferase enzyme 
(modified from Ryter et al., 2000 5). 
 
 
The bilirubin detectable in blood by clinically available measurement techniques is the total 
serum bilirubin (TSB), both conjugated, or direct bilirubin (CB), and unconjugated or indirect 
(UCB).  
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Due to its hydrophobic nature, almost all UCB is tightly but reversibly bound to albumin in 
adults 6 and -fetoprotein in newborns, to be targeted to the liver 7. Only less than 0.1% of the 
UCB is not bound to albumin and it is named free bilirubin (Bf) 8. This small portion of lipophilic 
bilirubin is able to passively diffuse through membranes and accumulate inside all tissues 9. 
In the liver, UCB can be converted into more soluble products prior to being secreted in bile 
10 through the glucuronidation process. Once in the proximity of the liver, UCB is able to enter the 
hepatocyte via passive diffusion 7 and/or transporters 11,12. At the sinusoidal membrane, UCB 
dissociates from albumin, it is internalized and transferred to the endoplasmic reticulum (ER) 
where it is conjugated with one/two molecules of glucuronic acid by the uridine 
diphosphoglucuronate glucuronosyltransferase enzyme (UGT1A1) 13.  
CB, in the form of mono and diglucuronides 14,15, is secreted into the bile canaliculus by the 
ATP-dependent transporter multidrug resistance-associated protein MRP2 16. A fraction of 
intracellular CB not excreted into bile is transferred back to the blood by the sinusoidal transporters 
MRP3 (ABCC3: ATP-binding cassette transporter 3) and reabsorbed in downstream hepatocytes 
via OATP1B1 and OATP1B3 transporters (organic anion-transporting polypeptide). This is a 
liver-blood shuttling loop for bilirubin glucuronide crucial to prevent saturation of biliary 
excretion 17,18. 
CB excreted in bile passes the small intestine and reaches the colon, in which the glucuronic 
acid is removed by intestinal bacteria, and the resulting bilirubin is converted to urobilinogen, 
oxidized to stercobilin and excreted by feces. Some of the urobilinogen is reabsorbed by the 
enterohepatic circulation and transferred to the kidney, in which it is transformed in urobilin and 
excreted by urine 19,20.  
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Figure 1-2. Bilirubin transportation across the hepatocyte. 
Hepatocytes are organized between the portal tract and the bile duct. In this scheme of the hepatocyte, the localization of 
transporters across the plasma membrane is evidenced. Bilirubin enters the hepatocyte through passive diffusion or OATP 
transporters at the level of the sinusoidal membrane. Once UCB is converted in BG (bilirubin glucuronides), it is secreted into the 
bile duct through ABC transporters (modified from van de Steeg E. et al. 2012 18). 
 
1.1.2 CLINICAL ASPECTS OF BILIRUBIN NEUROTOXIC 
PROPERTIES 
 
Bilirubin has a double-edged role in the body: antioxidant and protective on the one hand, 
whereas neurotoxic on the other hand, mostly depending on its concentration.  
The toxic effect is typically manifested in newborn babies and it is supposed to be due to the 
interaction between the level and the duration of central nervous system (CNS) exposure to Bf 21 
and the molecular characteristics of the developing CNS 22,23. Only Bf is able to cross the 
Hepatocyte 
Canalicular 
membrane 
Sinusoidal 
membrane 
ABCC3 
ABCC2 
ABCG2 OATP1B1/3 and 
PASSIVE 
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endothelial cells that form the Blood-Brain Interfaces (BBI) impairing the normal cellular function 
24,25.  
Neonatal jaundice has been noticed through the centuries, but the scientific description 
seems to have started in the last half of the 18th century. 
In 1904, Schmorl presented the results of autopsies of 120 jaundices babies and reported 
only six cases of a staining phenomenon of some brain areas, coining the term “kernicterus”, which 
refers to the intense yellow coloring of the basal ganglia and medulla oblongata 26. Due to this 
finding, the selective and observable deposition of bilirubin in specific brain regions has been 
considered the main cause of the bilirubin damage for several years.  
Later, this concept was doubt 27. The experimental finding that the same bilirubin 
concentration was measured in different brain regions of the well-characterized animal model for 
hyperbilirubinemia (Gunn rat) supported the idea that the selective brain damage observed could 
be due to the different regional vulnerability to bilirubin toxicity 28–30, rather than to the preferential 
bilirubin deposition in the brain.   
 
1.1.3 DISORDERS OF BILIRUBIN METABOLISM 
 
Abnormalities in bilirubin metabolism (uptake from the circulation, intracellular binding, 
and storage, conjugation, biliary excretion) may result in hyperbilirubinemia, that can be divided 
into two types: unconjugated (indirect) or conjugated (direct). 
In this work, I will describe only the unconjugated hyperbilirubinemia because it represents 
the main cause of bilirubin encephalopathies and the focus of this thesis. 
 
1.1.3.1 NEONATAL JAUNDICE 
Neonatal jaundice is a common and generally benign condition, affecting more than half of 
newborns, due to an abnormal elevation of circulating bilirubin in the transitional period after 
birth. The yellowish color of the skin and conjunctiva is a direct consequence of the increased 
levels of serum bilirubin, that reaches the peak at about 72 hours after birth (5-10 mg/dL) and 
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subsequently declines to normal adult levels in 7-10 days (≤1 mg/dL) 31. Physiologic jaundice is 
determined by a combination of several events. Firstly, the increased bilirubin production is due 
to a shortened red blood cell lifespan and subsequent increased catabolism of hemoglobin into 
UCB. Then, the bilirubin disposal mechanisms located in the liver are immature in neonates: low 
hepatocellular transporter levels, as well as low activity of UGT enzyme, results in retention of 
UCB in babies 31–33. Moreover, the conversion of UCB into urobilinogen processed by intestinal 
bacteria is not yet active. This benign condition is usually resolved during the first week of life 
without any kind of treatment 34–36.  
Hemolytic conditions, inherited defects in conjugation, prematurity, as well as 
epidemiologic or environmental risk factors could additionally contribute to neonatal 
physiological jaundice. If hyperbilirubinemia is not properly diagnosed, supervised and possibly 
treated, it may progress in more severe complications producing a complex pattern of neurologic 
dysfunctions. 
 
1.1.3.2 BILIRUBIN ENCEPHALOPATHY AND KERNICTERUS 
The extent and pattern of neurological damage and sequelae is influenced by the amount and 
the duration of bilirubin neurotoxicity. In particular, two conditions of bilirubin encephalopathy, 
with several levels of severity, have been well characterized from the clinical point of view: acute 
and chronic 36. 
Less severe hyperbilirubinemia can produce subtle encephalopathy, or bilirubin-induced 
neurological dysfunction (BIND). Typical disabilities without classical findings of kernicterus are 
movement disorders, isolated hearing loss and auditory dysfunction (AN auditory neuropathy; 
AD: auditory dys-synchrony) that could be associated with cognitive dysfunction 36. 
Acute bilirubin encephalopathy (ABE) includes abnormalities of tone (hypotonia and/or 
hypertonia), decreased feeding, lethargy, high-pitched cry. Fever and seizures may occur, at worst 
death 36. 
Chronic bilirubin encephalopathy, also called kernicterus, is characterized by a tetrad of 1) 
abnormal motor control, movements and muscle tone 2) auditory processing disturbance with or 
without hearing loss, 3) oculomotor impairments (upward vertical gaze), 4) dysplasia of the 
enamel of deciduous (baby) teeth. Selective damage of the globus pallidus pars externa (GPe) and 
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interna (GPi), substantia nigra reticulata, subthalamic nucleus (STN), brainstem auditory, 
vestibular, and oculomotor nuclei, hippocampus, cerebellum, was reported. Movement disorders 
are caused by the selective lesions in the basal ganglia. Abnormal tone and coordination may also 
correspond to lesions of the cerebellum and specific brainstem nuclei involved with truncal tone 
and vestibular function. Lesions of the auditory brainstem nuclei lead to auditory processing 
disorders, hearing loss/deafness 36. 
 
 
Figure 1-3. Jaundice and Kernicterus in newborns.  
Neonatal jaundice is a physiological condition characterized by excess bilirubin in blood that is easily detectable because of the 
yellow color of the skin and the eyes. Bilirubin can reach the brain passing the blood-brain barrier and lead to a more severe 
condition, named kernicterus. (ADAM encyclopedia). 
  
1.1.3.3 CRIGLER-NAJJAR SYNDROME 
Crigler-Najjar syndrome types I (CN1) and II (CN2) are rare, inherited autosomal recessive 
diseases that are characterized by lifelong non-hemolytic unconjugated hyperbilirubinemia 37. The 
risk of developing severe neurologic complications, such as movement and hearing impairments, 
and mental retardation, is high in patients with CN syndrome. Treatments are aimed at reduction 
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of serum bilirubin levels. Phototherapy is the routine treatment, but it becomes less effective after 
puberty because of skin thickening, pigmentation, and decreased surface area in relation to body 
mass. Plasmapheresis during a crisis is another possibility, but orthotopic liver transplantation is 
surely the only curative therapy 38. Gene therapy methods could be a promising solution: the 
correction of hyperbilirubinemia by the injection of a vector expressing the corrected human 
UGT1a1 was reported in Gunn rats 39 and also in hyperbilirubinemic mice model 40,41. 
High serum levels of UCB are due to the partial or complete absence of the enzyme uridine 
diphosphate-glucuronosyltransferase 1 (UGT1A1), located in the liver and responsible of the 
bilirubin glucuronidation. The UGT1A1 is encoded by the UGT1a1 gene, which contains five 
consecutive exons located at the 3’ end of the UGT1A locus on chromosome 2q37. Point mutations 
of the gene UGT1a1 are the basis of differences in CN syndrome. While CN1 results from genetic 
changes that cause premature truncation or critical amino acid residue substitution, CN2 is caused 
by substitution of single amino acid residues that markedly reduce, but do not abolish, the catalytic 
enzyme activity 42,43. Therefore, the level of serum bilirubin is different in CN1 and CN2: higher 
in the first syndrome (20-25 mg/dL, until 50 mg/dL during fasting or intercurrent illness), lower 
in the second (7-20 mg/dL, until 40 mg/dL during fasting or intercurrent illness), resulting in less 
severe complications. In CN2, phenobarbital administration is able to reduce over 25% serum 
bilirubin level 42,44. 
 
1.1.3.4 GILBERT’S SYNDROME 
Other names for Gilbert’s syndrome are “constitutional hepatic dysfunction” or “familial 
nonhemolytic jaundice” 45. This condition is characterized by mild, chronic, and unconjugated 
hyperbilirubinemia in absence of hemolysis or any other liver diseases. The hepatic-UGT activity 
reduction leads to increase of serum bilirubin level up to 3 mg/dL or higher during fasting or 
intercurrent illness 46.  
This syndrome is due to the TA insertion within dinucleotide repeat in the promoter region 
of UGT1a1 gene. The normal TATAA element sequence is A(TA)6TAA, whereas in Gilbert 
syndrome the sequence is A(TA)7TAA. The variant TATAA element reduces the expression of 
the structurally normal enzyme 47.    
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Gilbert’s syndrome is considered innocuous, so no treatment is required, but its diagnosis is 
important to avoid confusion with other hepatobiliary disorders leading to hepatic injury. 
 
1.1.4 PREVENTION AND TREATMENT OF SEVERE 
HYPERBILIRUBINEMIA 
 
The clinical practice guidelines reported by the AAP (American Academy of Pediatrics) 
Subcommittee on Hyperbilirubinemia (2004) for the management of jaundice were addressed to 
reduce the incidence of severe hyperbilirubinemia and bilirubin encephalopathy in newborns 48,49. 
The main purposes of these guidelines are:  
 development of newborn nursery protocol for identification, evaluation, and 
management of hyperbilirubinemia in the hospital;  
 measurement of the total serum bilirubin (TSB) in the first 24 hours;  
 provide information about newborn jaundice to parents;  
 supply indications for the use of phototherapy, exchange transfusion and newer 
pharmacologic therapies 48,49.  
 
1.1.4.1 PHOTOTHERAPY 
Phototherapy represents the conventional treatment for hyperbilirubinemia and its aim is to 
reduce UCB concentration to non-toxic levels, preventing its deposition into the brain tissue. It 
was firstly introduced by Cremer and colleagues in 1958 50. The principle of action is based on the 
capacity of the blue-green light with a wavelength around 400-520 nm to photo-oxidize the 
hydrophobic UCB to more polar isomers that can be easily excreted in the urine and stool 51.  
The efficacy of phototherapy is determined by some relevant aspects: the wavelength range, 
the intensity of the light and the body surface exposed to the light 52. 
Rare side effects of phototherapy were observed: development of allergic diseases, 
impairment of thermoregulation, retinal impairments, dehydration are few examples 53. 
Considering that bilirubin neurotoxicity is principally due to the bilirubin portion not bound to 
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albumin (Bf) and poor information was collected about the potential toxicity of bilirubin 
breakdown products, a recent study conducted by Jasprova and colleagues demonstrated that 
bilirubin photoisomers not only don’t interfere in bilirubin-albumin interaction but also in cell 
viability 54. 
 
1.1.4.2 EXCHANGE TRANSFUSION 
Exchange transfusion is recommended in infants with very severe unconjugated 
hyperbilirubinemia (serum bilirubin level of 20 mg/dL or higher) and the risk to develop acute 
bilirubin encephalopathy, with insufficient response to phototherapy. With this very invasive 
treatment, hyperbilirubinemic blood is removed and replaced with fresh non-jaundiced blood, also 
providing fresh albumin with binding sites for bilirubin 55. Adverse events such as cardiac arrest, 
coagulopathies, thrombosis are frequent and the mortality rate is high (03-2.0%) 56. 
 
1.1.4.3 PHARMACOLOGICAL STRATEGIES 
Alternative treatment strategies have concentrated on pharmacological approaches 57 with 
the aim of decreasing the production of UCB, increasing the hepatic clearance of UCB, 
interrupting the enterohepatic circulation of UCB. 
UCB production can be decreased using two inhibitors of HO activity: metalloporphyrins 58, 
a synthetic heme analog in which other metals replace the central iron atom of heme, or D-
penicillamine, a chelating agent 59. Both these drugs need further clinical investigation regarding 
safety and efficacy, before routine clinical use. 
Increasing UCB conjugation could be a possible strategy to reduce plasma UCB levels. 
Phenobarbital is an anti-epileptic drug that is able to enhance UCB clearance and conjugation by 
activating the phenobarbital enhancer module in the promoter sequence of UGT1a1 60. It has been 
used to treat neonatal jaundice due to several reasons since 1960, and it is also useful to distinguish 
between type I and type II Crigler-Najjar syndrome because in the first case it is not effective.  
Intravenous immune globulin (IVIG): reduces jaundice in many cases of neonatal 
isoimmunization. Recommended doses are 500 mg/Kg bodyweight of human virus inactivated 
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IVIG, infused over a 2-hour period. The risk for not responding to IVIG administration if bilirubin 
rate rises ≥1 mg/dL/h 61,62. 
Pharmacologic agents that provide neuroprotection by directly targeting the adverse effects 
of unconjugated bilirubin in the CNS are attractive options. Minocycline is a semi-synthetic 
second-generation tetracycline that seems to have protective effects. While it contrasts apoptosis, 
inflammation, and excitotoxicity in vitro, instead it prevents bilirubin-induced cerebellar 
hypoplasia and auditory dysfunction in Gunn rats 63,64. Unfortunately, the use of this drug presents 
relevant side effect on developing bone and dentition. 
 
1.1.5 ANIMAL MODELS FOR HYPERBILIRUBINEMIA 
 
In 1938, Gunn Charles Kenneth published an important paper in The journal of Heredity 65, 
describing a genetic mutation in the Wistar rat strain (Rattus norvegicus) that results in an 
autosomal recessive hereditary non-hemolytic unconjugated hyperbilirubinemia. The mutant rats 
have been named Gunn rats (commercial name: Hds Blue:Gunn-UDPGTj) after their discoverer.  
The abnormal increased amount of bilirubin pigment is due to the absence of bilirubin 
glucuronidation activity in the liver caused by the Ugt1a single-base deletion frameshift mutation 
that results in inactive bilirubin-conjugating enzyme UDP-glucuronyltransferase 66, causing 
jaundice, represented by the “j” in the name of the strain. The enzyme defect is one of the mutations 
present in the human Crigler-Najjar type I syndrome 67. 
These animals are normal at birth and become jaundiced within 24 hours. Serum bilirubin 
levels continue to rise in hyperbilirubinemic (jj) newborn until about 15 mg/dL during the first 
two weeks of life and decline to adult levels (around 6 mg/dL) after approximately 30 days 68,69. 
In contrast, homozygous (JJ) or heterozygous (Jj) non-hyperbilirubinemic animals do not show 
abnormalities, having identical bilirubin levels of about 0.20 mg/dL.  
Colonies of Gunn rats are maintained throughout the world, with varied breeding practices 
fostering the development of distinct subpopulations of Gunn rats 70. Besides the total bilirubin 
concentration, hyperbilirubinemic animals present some recurrent phenotypic characteristics, even 
if relevant differences could occur in some subpopulations more than in others. Symptoms such 
as lag growth 71, neurological difficulties like occasional ataxia, wobbly gait or partial paralysis of 
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the hind limbs, different mortality rate were observed decades ago 70,72,73. By the time, the Gunn 
rats have been changed showing a decrease in the severity of the phenotype, even if the most 
important typical features, the high level of UCB and the cerebellar hypoplasia, have been well 
preserved. For this reason, Gunn rat remains one of the most representative animal models for the 
study of hyperbilirubinemia. 
As previously mentioned, a part high level of serum UCB, another important hallmark is the 
brain selective impairment, especially the marked cerebellar hypoplasia 28,74–76. Since the rat 
cerebellum is known to undergo to a complex and intensive developmental activity, especially 
after birth 77, cerebellar hypoplasia could be the result of a combination of the postnatal cerebellar 
neurogenesis and the action of bilirubin. The first abnormalities in the cerebellum were found over 
the age of 3 days after birth 78, but the critical period for bilirubin-induced cerebellar hypoplasia 
was identified 6-10 days after birth 28,73,75.  
Both total cerebellar volume and growth of cerebellar vermis and lobules, especially the 
anterior, are significantly reduced in jj animals if compared to non-hyperbilirubinemic controls. 
Histological investigations showed a marked alteration of cerebellar layer architecture: 
external granular layer (EGL), molecular layer (ML) and internal granular layer (IGL) are thinner, 
presenting a lower cell density, depending on the age considered. Purkinje cells are the most 
degenerated in terms of density and structure: the most striking histological feature are cytoplasmic 
alterations, such as vacuolation of Golgi vesicles or cisternae and dilated endoplasmic reticulum 
74–76,79. Also, the Purkinje cell layer appears extremely disorganized, being buried in the internal 
cell layer. Synaptogenesis and myelination are also reported to be compromised 76,80. A study 
performed in our lab both in vivo and in vitro showed that the typical cerebellar hypoplasia of the 
Gunn rat might be in part due to the cell cycle perturbation and the enhancement of apoptosis 
triggered by the high level of UCB 79.  
Despite the selective deposition of bilirubin in the brain has been considered for several 
years the main cause of regional damage observed in the brain, findings from different studies on 
Gunn rat revealed that there was no significant differences in the bilirubin concentrations between 
brain regions 28–30. Thus, the reasons for the brain regions selective intrinsic vulnerability need to 
be further explored. 
Later on, the hyperbilirubinemic model has been recreated in the mouse. Some research 
groups focused on the examination of the physiological importance of the UGT1A1 in the 
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metabolism of bilirubin and produced genetically engineered mice in which the UGT1A1 enzyme 
is inactive. One knockout mouse for UGT1 (UGT1-/-) was developed by Nguyen and colleagues, 
inserting a NEO cassette that produced the complete interruption of the exon 4 of the UGT1 gene 
cluster 81. Another mouse model was generated some years later by the introduction of a 1-base 
deletion in UGT1 exon 4 that produced an in-frame premature stop codon, generating a truncated 
and inactive form of the protein 40. Despite the same high TSB level and cerebellar impairment, 
the phenotype of the mice model is more severe than that observed in Gunn rat: stronger brain 
damage due to UCB results in death within two weeks after birth. 
 
 
 
 
 
 
   
 
Figure 1-4. Gunn rats and brain comparison between jj and JJ/Jj. 
(A) Gunn rat 2 days after birth. To be noticed, the difference in skin color that allow the recognition of the hyperbilirubinemic 
animals (jj) on the left and the non-hyperbilirubinemic ones, both wild type (JJ) and heterozygous (Jj), on the right. (B) The brain 
of Gunn rat are macrospically characterized by differences in color and in the cerebellum size: on the left brain of 
hyperbilirubinemic rat (jj) with evident cerebellar hypoplasia, on the right brain of non-hyperbilirubinemic animal.  
 
 
1.1.6 MOLECULAR BASIS OF BILIRUBIN NEUROTOXICITY 
 
Bilirubin toxicity for the central nervous system has been widely studied for decades all over 
the world in vitro, ex vivo, and in vivo. Although progress has been reached in clarifying the 
principal causes of bilirubin-induced encephalopathy, the complete sequence of molecular events 
that produce brain damage is not fully understood. 
Bilirubin has been reported to be selectively neurotoxic both for specific brain region and 
cell types 23,82–84, due to different bilirubin exposure and cell sensitivity to injury 85.  
jj JJ, Jj 
jj JJ, Jj 
A B 
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Neurons are the most sensitive cells to UCB attack. Macroscopical changes, such as 
reduction of dendrites and axons arborization as well as reduction of dendritic spines and synapses 
have been observed 80,86–88.  
Besides neurons, other cell types have been reported to be responsive to UCB action. 
Microglia 89,90 and astrocytes 91 secrete inflammatory mediators and glutamate to contrast the 
bilirubin-induced neurotoxicity. The inflammatory, excitotoxic and oxidative stress response to 
UCB insult have been confirmed in recent works using organotypic cultures 23,92.  
Typical lipidic nature of plasma membrane, especially myelin-rich membrane 80,93,94, allows 
bilirubin to enter the cells diffusing spontaneously through the phospholipidic bilayer perturbing 
its permeability and physiology 95,96. Increased UCB concentration was also reported to 
compromise oligodendrocyte maturation and myelination 97. 
The activation of complex signal cascades culminates to survival or death processes. 
Examples of the processes modulated by UCB are the following: cell cycle perturbation 79, 
oxidative stress activation 83,98,99 and antioxidant response 100, excitotoxicity 101–103, apoptosis 
pathway activation 84,104, inflammation 84,91.  
Bilirubin can also modulate potential protection/adaptation mechanisms against its toxicity 
for the brain. The real efficiency on adaptation and protection mechanisms against bilirubin 
toxicity is still difficult to understand and evaluate. Examples are: transporters at the level of BBI 
that seem to be responsible for bilirubin efflux from the brain 105,106, detoxification mechanisms 
involving the glutathione S-transferase (GSTs) enzymes 68,107, and bilirubin oxidation by “bilirubin 
oxidase” that belongs to the cytochromes P450 family 27,30,108. 
All the processes mentioned above are characterized by the modulation of a wide range of 
genes and proteins. 
Two interesting studies, conducted on SH-SY5Y neuroblastoma cell line, showed that UCB 
induces the expression of proteins implicated in cell proliferation, intracellular trafficking, protein 
degradation and oxidative stress response 109, as well as the significant upregulation of around 230 
genes after 24 hours of treatment with 140 nM Bf, based on a False Discovery Rate (FDR) of about 
10% 110.  
Several studies that aimed to deepen specific pathways triggered by UCB reported the 
modulation of the mRNA expression of genes involved in.  
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The cell cycle perturbation was accompanied by the modulation of cyclins and cyclin-
dependent kinase 2 79. 
The oxidative stress of the endoplasmic reticulum was counteracted by the activation of the 
antioxidant Nrf2 pathway, with a subsequent up-regulation of cytoprotective genes that mediate 
cell survival (xCT, GLY1, γGCL-m, γGCL-c, HO-1, NQO1, FTH, ME1, ATF3) 100. Another marker 
of oxidative stress (SRXN1) was also up-regulated. Alteration of oxidative stress was also 
demonstrated in other studies 5,99,103,111,112. 
Apoptosis was mediated by the activation of pro-apoptotic CHOP 84. The activation of the 
apoptotic process was confirmed also in other works 102,104. 
Inflammation markers, such as Il1β, Il6, Cox2, IL8, TNFα, resulted to be increased 23,84. The 
role of bilirubin in triggering the inflammation pathways was reported also in other proteomic 
studies 89,97,113. 
Bilirubin oxidation by cytochrome P450 family of enzymes was probably driven by the 
activation of the transcription of Cyp1a1 and Cyp1a2 30,108. 
mRNA of the Mrp1 bilirubin transporter, located at the level of the blood-brain-interfaces, 
was reported to be enhanced 106. 
The detoxification mechanism determined by the activation of the glutathione enzyme was 
also induced by the up-regulation of mRNA encoding Na+-independent cysteine:glutamate 
exchanger System Xc- (SLC7A11 and SLC3A2 genes) 107. Another work not already published 
conducted in our lab showed the modulation of other relevant genes linked to the glutathione 
system (Gstα2, Gstα3, Gstμ3, Gstμ4, Gstπ). 
The impairment of the oligodendrocytes myelination process was combined with the 
modulation of the mRNA levels of two markers of oligodendrocytes differentiation (Olig1 and 
Olig2) 97. 
These intricate interacting pathways, that are also characterized by significant modulation 
of gene expression, suggest that mechanisms that have a crucial role in the regulation of gene 
expression, such as epigenetic mechanisms, should have a strong impact in unconjugated bilirubin 
toxicity.   
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1.2 EPIGENETICS 
 
The term “epigenetics”, coined by the developmental biologist Conrad H. Waddington 
during the mid-twentieth century, was derived from the Greek word “epigenesis” that literally 
means “in addition to changes in genetic sequence” 114. During the 1990s growing interests on 
epigenetics lead to an evolution of this term, that started to include any process that program genes 
to be differentially expressed in different context, altering gene function without changing the 
DNA sequence, and leads to modifications that can be transmitted to daughter cells 115,116. 
Epigenetic processes are involved in the regulation of gene expression in many physiological 
processes, and epigenetic aberrations often contribute essentially to the onset and progression of 
human diseases, such as cancer, neurological disorders, inflammatory diseases and viral infections, 
via the loss or gain of function of epigenetic regulatory proteins 117. 
Many types of epigenetic processes have been identified, such as chemical modifications at 
the level of nucleotides (DNA methylation and RNA interference (RNAi)), modifications at the 
level of histones (posttranslational modifications (PTMs) of histone proteins and histone variants), 
and nucleosome remodeling, (ATP-dependent processes that regulate the accessibility of 
nucleosomal DNA). 
Most transcriptional regulatory events cause changes to chromatin structure and 
composition, which result from the recruitment of chromatin-modifying enzymes by transcription 
factors and by transcriptional machinery itself 118,119. 
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Figure 1-5. Mechanisms involved in chromatin modification. 
DNA methylation, histone modification, remodeling by chromatin-remodelling complexes, insertion of histone variants, non-
coding RNAs (ncRNAs). All are essential contributors to the development and cell-fate determination of tissues (modified from 
Dulac 2010 120). 
 
 
Chromatin is the state in which DNA is packaged within the cell. The fundamental unit of 
chromatin is the nucleosome, a protein-DNA complex discovered in 1974. Each individual 
nucleosome consists of an octamer of the four globular core histones (H3, H4, H2A, H2B) around 
which 147 base pairs of DNA are wrapped. Each nucleosome core particle is separated from the 
next by a region of DNA linker about 80 nucleotide pairs long. The histone core has an NH2-
terminal amino acid “tail”, which protrudes out of the tight DNA-histone core 121,122.  
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Figure 1-6. Structure of the nucleosome core at 1.9 Å resolution.  
DNA strands are cyan and brown. The histone-fold domains of the histone proteins are blue for H3, green for H4, yellow for H2A 
and red for H2B. The histone-fold extensions and N-terminal tail regions are white (modified from Davey et al, 2002 122 ). 
 
 
The NH2-terminal tails are subjected to several covalent modifications, defined as post-
translational modifications (PTMs), such as acetylation, methylation, phosphorylation, 
ubiquitination, and sumoylation. Due to their chemical properties, these epigenetic modifications 
can alter the condensation of the chromatin and the accessibility of the DNA to the transcriptional 
machinery 123,124. The more condensed and “inaccessible” form of chromatin (heterochromatin) is 
converted in a less packed and more “accessible” chromatin (euchromatin), disrupting the contact 
between nucleosomes and DNA 118,119. Thus, basic biological functions, i.e. transcription, 
replication and repair of DNA, are allowed thanks to the turning on or keeping off specific genes. 
The timing of the appearance of a modification depends on the signaling conditions within the 
cell.  
 
DNA strands 
Histone N-terminal tail 
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1.2.1 HISTONE ACETYLATION 
 
Histone acetylation has recently received great attention, especially in the nervous system 
116,120,125–131, because of the knowledge of the enzymatic activity machinery and signal transduction 
mechanisms that regulate this post-translational modification, both in physiological and 
pathological conditions.  
The acetylation and deacetylation of histones, occurring on lysine (K) residues located on 
the histone tails are dynamic processes, balanced in healthy conditions 132. Two classes of 
functionally antagonistic enzymes, the histone acetyltransferases (HATs) and the histone 
deacetylases (HDACs), are responsible for the addition or removal of the acetate groups from 
acetyl coenzyme A (acetyl-CoA) 133. The acetyl group addition neutralizes the positive charge of 
the ε-amino group of the lysine, leading to a decreased affinity between the histone tail and the 
negatively charged DNA 134. The consequence of this is a remodeling of chromatin from a tightly 
packed configuration to a loosely packed configuration, which subsequently leads to 
transcriptional activation. Conversely, the removal of the acetyl groups may cause chromatin 
structure to condense and result in transcriptional silencing 123,124,135–139.  
The pivotal role of histone acetylation in the activation of gene transcription is also 
determined by the fact that HAT complexes possess coactivator activity: they promote TATA-
binding protein (TBP) or other general transcription factor association with the basal promoter. In 
fact, the acetylation is enriched at specific sites in the promoter and 5’end of the coding regions of 
genes that are ready to be transcribed 124. 
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Figure 1-7. Transcriptional activation by histone acetylation.  
The coactivator-acetyltransferase (HAT) complex (blue) is targeted by the DNA-binding transcription factors (green) to open the 
condensed and inactive chromatin. The HAT complex decondenses chromatin by acetylation of the histone tails, that starts to be 
transcriptionally active. The HAT complex also facilitates recruitment of the basal transcriptional machinery (violet) to the 
accessible promoter chromatin.  
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1.2.2 HISTONE ACETYLATION IN NEUROPATHOLOGIES 
AND NEW THERAPEUTIC PERSPECTIVES  
 
The epigenetic regulation of gene expression plays an important modulatory role in many 
biological processes throughout the brain, such as development and differentiation, synaptic 
plasticity, learning, and memory, as well as the maintenance and survival of neurons 116,128.  
The brain is one of the most heterogeneous tissues overall, thus the complexity of epigenetic 
modifications is further potentiated. Different brain regions respond differently to the same 
environmental challenge, as well as the same brain area, made up of the intricate interaction of 
different cell types, could be characterized by a heterogeneous epigenetic profile 130. 
Over the past decade, epigenetic regulation has been widely explored and considered an 
integral part of a multitude of physiological brain function both in health and disease.  
Aberrant epigenetic programs of gene expression in neurodevelopmental, psychiatric, 
neurodegenerative disorders have been described in several studies. In particular, histone 
acetylation was the most studied chromatin modification because of its relevant role in 
neuroplasticity 120,126,129,140,141 and memory formation 142. The deregulation of the HAT/HDAC 
balance, resulting in alterations of gene transcription and common cell damage mechanisms, 
including excitotoxicity, calcium overload, oxidative stress, acute inflammation, and apoptosis, 
has been implicated in several neurological disorders 143. 
Examples of common neurological diseases in which this mechanism is unbalanced are 
Alzheimer’s Disease (AD) and dementia 142,144–146, Autism Spectrum Disorder (ASD) 147,148, 
Multiple Sclerosis (MS) 149, Amyotrophic Lateral Sclerosis (ALS) 150, Parkinson’s Disease (PD) 
151–153, stroke and brain trauma 143,154. 
Also, rare diseases were reported, such as Huntington’s Disease (HD) 155–157, Friedreich’s 
ataxia (FRDA) 158,159, Rett syndrome (RTT) 160–162, Niemann-Pick disease (NPD) 163, and 
psychiatric disorders 164–168, like schizophrenia.  
Once CNS disorders were demonstrated to share common mechanisms of cell damage that 
are triggered also by epigenetic alterations, the question that researchers worldwide purpose to 
answer is if it is possible to correct these epigenetic alterations.  
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Certainly, therapeutics targeted at epigenetic mechanisms (via epigenetic drugs), that despite 
the reversibility of epigenetic modification, would represent a recent ambitious challenge in the 
approach to treat CNS conditions 115,169. 
Several epigenetic drugs are approved as drugs for other indications, for example, cancer, or 
are both in pre-clinical and clinical trials.  
Examples of epigenetically targeted drugs that may have used in CNS indications and are 
able to reverse histone acetylation aberrations include the following: HDAC inhibitors 143,170–176 
and HAT inhibitors 169,177–179.  
The knowledge about the efficacy of the HDACis against several diseases was extensively 
consolidated, in contrast, despite their potential, the inhibitors for HATs need further 
investigations because too many questions remain unsolved between their biological activity in in 
vitro studies and their use as therapeutic agents 179.   
For this reason, I will mention in this chapter only some examples of the most relevant 
studies that showed the neuroprotective role of the HDAC inhibitors against programmed cell 
death or excitotoxicity in some brain pathologies. 
Current HDAC inhibitors can be divided into three families: the hydroxymates (trichostatin 
A and vorinostat), the short-chain fatty acids (sodium butyrate and valproate), and the benzamides 
(MS-275). Before knowing their activity on histone acetylation, some of these compounds, such 
as valproate, were widely used mainly as mood stabilizers in neuropsychiatric disorders. 
The promising clinical application of the HDAC inhibitors was firstly targeted to the 
treatment of different types of cancer 180–182, with hundreds of clinical trials ongoing, and more 
recently to neuropathologies. 
In mouse models for the most common neurodegenerative disorder, Alzheimer’s disease, 
HDAC inhibitors tested were capable of reversing memory deficits 183,184. Clinical trials on the 
efficacy and safety of nicotinamide (ClinicalTrials.gov: NCT00580931) and valproate 
(ClinicalTrials.gov: NCT00071721 and NCT01729598) in Alzheimer’s disease patients have 
started a few years ago.  
HDACis were also tested in Parkinson’s in vivo models. Valproic acid, sodium butyrate and 
trichostatin A (TSA) were demonstrated to have survival-promoting and protective effects on 
dopaminergic neurons 185,186. Moreover, sodium butyrate was reported to attenuate the motor 
deficits in 6-hydroxydopamine (6-OHDA)-induced experimental PD animal models 187.  
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The effectiveness of HDAC inhibitors was also demonstrated in amyotrophic lateral 
sclerosis. Preclinical studies reported that TSA was able to delay the disease progression and 
increase the ALS mice survival 188,189, and some clinical trials were launched to test valproic acid 
and sodium valproate in human patients (ClinicalTrials.gov: NCT00107770 and NCT00136110). 
Several studies reported the anti-inflammatory, restorative and neuroprotective effects of 
HDACis also in stroke 190–193 and brain trauma 194–197.  
The neuroprotective properties of HDAC inhibitors were observed also in animal models for 
the rare Huntington’s disease. An amelioration of the neurodegenerative phenotype and the 
transcriptional abnormalities after the treatment by HDAC inhibitors was reported 198–200. The 
candidate HDACi sodium phenylbutyrate was tested in human patients and a phase II clinical trial 
was launched in 2005 (ClinicalTrials.gov: NCT00212316; Hogarth 2007). 
Recent interesting works focused on neurodevelopmental disorders revealed the 
amelioration of some typical signs after the therapy with HDACis. Animal models for autistic 
spectrum disorder showed an amelioration of their social behavior and cognition deficits after the 
treatment with sodium butyrate 201, or valproate 202. Clinical trials were also launched to test the 
valproate on children and adolescent autistic patients (ClinicalTrials.gov: NCT00211757). The use 
of HDAC inhibitors could have interesting new implications also in Friedreich Ataxia mouse 
model 158,159 and Rett syndrome 203. 
This intriguing general picture of the involvement of epigenetic machinery in 
neurodevelopmental, neuropsychiatric and neurodegenerative disorders, with the original and 
attracting possibility to restore these diseases, need to be better clarified and completed. 
Especially the therapeutic potential of the drugs that act on histone acetylation mechanism 
might pertain also to the hyperbilirubinemic condition. 
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Figure 1-8. Effect of HDAC inhibitors on chromatin opening and transcription activation. 
 The action of the enzymes histone acetyltransferases (HATs) and histone deacetylases (HDACs) determines the 
acetylation/deacetylation of the histone lysine residues and the subsequent opening/closing of the chromatin structure and 
activation/deactivation of transcriptional gene expression. HDAC inhibitors block the deacetylation leading to a more relaxed 
chromatin conformation and transcriptional upregulation.  
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2 AIMS 
 
 
The selectivity of bilirubin toxicity in specific brain regions, despite the same bilirubin 
level detected in each of them, and its capability in altering gene expression have been widely 
investigated and confirmed. 
The involvement of epigenetic mechanisms able to regulate the expression of genes that 
control damage/resistance pathways in bilirubin neurotoxicity has not been explored till now. 
 
In the present study we intend to: 
 
 Evaluate the presence of altered levels of the acetyl-histone H3 (lys 14) in 5 brain regions 
(cortex, cerebellum, hippocampus, superior colliculi, inferior colliculi) of 
hyperbilirubinemic animals vs control at 4 post-natal ages.  
 Individuate the genes regulated by acetyl-histone H3 (lys 14) in hyperbilirubinemic 
animals vs. control. 
 Interpret the biological effects of this epigenetic modulation. 
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3 MATERIALS AND METHODS 
 
 
3.1 EXPERIMENTAL PLAN 
 
The involvement of histone acetylation in the brain of hyperbilirubinemic animals was 
explored in this study starting by the evaluation of the acetyl histone H3 (lys 14) (H3K14ac) 
levels by Western blot. Thereafter, a map of the genes regulated by the H3K14ac was obtained 
by chromatin immunoprecipitation assay followed by sequencing of the DNA fragments (ChIP-
Seq). By the comparison of the list of ChIP-Seq genes present in hyperbilirubinemic subjects 
vs. controls, both the genes which transcription was activated as well as silenced in 
hyperbilirubinemia were extrapolated.  
Finally, the histological analysis was performed as a relevant support for the biomolecular 
interpretation of the genetic results. 
 
 
3.2 ANIMAL MODEL AND BRAIN REGIONS 
DISSECTION 
 
Gunn rats, at two (P2), nine (P9), seventeen (P17) days after birth, and adults (more than 
60 days after birth) were obtained from the Specific Pathogen Free (SPF) animal facility of 
CBM S.c.a.r.l. (AREA Science Park, Basovizza). Hyperbilirubinemic homozygous (jj) Gunn 
rats, and normo-bilirubinemic homozygous (JJ) or heterozygous (Jj) littermates as control were 
used. 
This study was authorized by the local ethical committee for animal care and by the 
competent Italian Ministry. Animal care and procedures were performed according to the 
guidelines approved by the Italian Law (decree 87-848) and European Community directive 
  MATERIALS AND METHODS 
  
 
27 
 
(86-606-ECC). Maximal effort to minimize the number of the animals and their sufferance was 
done (RRR rule). 
Animals were sacrificed by decapitation, under deep anesthesia for the cases that required 
it, according to the ethical rules. The anesthesia was administered by intramuscular injection of 
a solution composed by Rompun 2% (dose 1.5 mg/100Kg) and Zoletil 100 (dose 20 mg/Kg). 
Brains were removed and placed in ice-cold PBS (137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 1.8 mM KH2PO4, pH 7.4). Under the stereomicroscope, cortex (Cx), cerebellum 
(Cll), inferior colliculi (IC), superior colliculi (SC) and hippocampi (Hip) were dissected, 
cleared from meninges and choroid plexuses. Cerebella were carefully weighted to evaluate the 
cerebellar size, as a measure of the hypoplasia, characterizing the hyperbilirubinemic Gunn rats. 
All the brain regions were stored at -80°C until use. 
 
 
 
 
 
 
Figure 3-1. Brain from P9 jj rat, dorsal view, and dissection procedure. 
Brain regions of interest were carefully dissected. (A) Entire brain vision with in evidence Cortex (Cx), Superior Colliculi (SC), 
Inferior Colliculi (IC) and Cerebellum (Cll). (B) Cll was removed and cleared from meninges and choroid plexuses. (C) View 
of the Hippocampus (Hip) in both the hemispheres.  
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3.3 GENOTYPING 
 
At birth, homozygous jaundice pups (jj) were easily distinguished from the non-
hyperbilirubinemic littermates by simple examination of the yellow coloration of the tegument. 
The genotyping procedure is necessary to distinguish the non-hyperbilirubinemic wild type (JJ) 
and the heterozygous animals (Jj), by the enzymatic restriction of PCR fragments encompassing 
the point mutation in the common exon of the UGT1 gene family.  
Briefly, rapid whole genome DNA extraction was performed using the HotSHOT 
method: around of 2 mm of rat tail was heated at 98°C for 1 hour in 75 μL of buffer (25 mM 
NaOH, 0.2 mM EDTA) and then neutralized with an equal volume of 40 mM Tris-HCl pH 5.5 
buffer. 
 The amplification of the UGT1a1 genomic sequence was performed by the PCR method 
diluting the sample and the UGT1a1 gene specific primers (Forward: 
GGGATTCTCAGAATCTAGACATTGT; Reverse: TCGTTTGTTCTTTTCTATTACTGACC) 
in the SSo AdvancedTM Universal SYBR® Green Supermix (BioRad, Hercules, CA, USA) 
for a total volume of 30 μL. The PCR conditions were settled up as reported below. 
 
 
 
 
 
Table 3-1. PCR parameters for the amplification of the UGT1a1 gene. 
 
 
The control of the PCR product and the DNA quantification were performed by gel 
electrophoresis. 
10 μL of the amplicon were digested at 60°C for 3 hours in 30 μL mix prepared with 3 
μL of NEBuffer 3.1 10X (B7203S, New England BioLabs®Inc, MA, USA), 0.3 μL of the 
restriction enzyme BstNI, 100% activity in NEBuffer 3.1 (R0168S, New England BioLabs®Inc, 
MA, USA). 
Cycle Step Temp Time Cycles 
Initial Denaturation 94°C 3 min 1 
Denaturation 94°C 1 min 
Repeated 35 times Anneal 55°C 1 min 
Extension 72°C 1 min 
Final Extension 72°C 5 min Repeated 80 times 
Infinite hold 4°C ∞  
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The amplicon underwent electrophoresis using 3% agarose gel. The results were observed 
under UV light with a transluminator (Euroclone, Milan, Italy) and pictures were taken with a 
KODAK DC290 Zoom Digital Camera (Kodak Rochester, NY, USA). 
 
 
3.4 TOTAL SERUM BILIRUBIN DETERMINATION 
 
Blood was obtained from the animals by decapitation under anesthesia when required by 
the ethical rules as reported above, and centrifuged at 2000 g for 10 min, RT, twice. Serum was 
collected under the dim light condition to minimize bilirubin photo-oxidation and immediately 
frozen at 20°C until use.  
The quantification of total bilirubin in serum was performed following the Jendrassik-
Gròf method based on the diazo-reaction 204.  
Briefly, bilirubin in serum was coupled with diazotized sulfanilic acid (Sulfanilic Acid 
solution: 28.9 mM C6H7NO3S, 15 mL HCl 1N; Sodium Nitrite solution: 72.45 mM NaNO2; 
sulfanilic acid and sodium nitrite solutions are mixed in 40:1 ratio to prepare diazo reagent), 
and caffeine reagent (0.41 M CH3COONa, 0.39 M C6H5COONa, 0.01 M EDTA, 0.19 M 
C8H10N4O2) to form a pink color compound. Ascorbic acid (0.23 M C6H8O6) was used to block 
the reaction. The final addition of alkaline tartrate solution (0.40 M NaOH, 1.13 M 
KNaC4H4O6*4H2O) converted the pink acid bilirubin to green colored compound (peak 
absorbance: 607 nm). The intensity of the color produced is directly proportional to total 
bilirubin present in serum. For the final calculation of bilirubin concentration, the absorbance 
values of each sample were interpolated to a standard curve performed by a dilution of a stock 
solution of bilirubin (bilirubin maximum concentration: 0.34 mM; bilirubin minimum 
concentration: 8 μM).  
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3.5 TOTAL PROTEIN EXTRACTION AND WESTERN 
BLOT 
 
The brain regions of interest (Cx, Cll, Hip, IC, SC) were dissected and mechanically 
homogenized by glass-glass Dounce. Proteins were extracted using the brain homogenization 
buffer (sucrose 0.25 M, KH2PO4 40.2 mM, K2HPO4 9.8 mM, EDTA 1 mM, DTT 0.1 mM, 
pH 7.4) and quantified by the Bicinchoninic Acid Protein Assay (BCA) 205, following the 
instruction provided by the supplier (B-9643 and C2284, Sigma, Missouri, USA). 
15-25 μg of proteins were denatured with 10% of β-mercaptoethanol (Sigma Chemical, 
St. Louis, MO, USA) and by 5 min boiling. Then, samples were loaded and separated by 12% 
sodium dodecyl sulphate-polyacrylamide gel (SDS-PAGE) by electrophoresis (electrophoresis 
buffer: 25 mM Tris-Base, 192 mM glycine, 0.1% SDS) in a Hoefer SE 250 System (Amersham 
BioSciences, UK). Molecular weight standards (10-170 kDa, #26616, Thermo Fisher 
Scientific, Waltham, MA, USA) were used as marker proteins.  
After SDS-PAGE, proteins were electro-transferred with a wet blotting system at 100V 
for 60 min (Bio-Rad Laboratories, Hercules, CA, USA) onto immune-blot PVDF membranes 
(0.2 μm; Whatman Schkleicher and Schuell, Dassel, Germany), in transfer buffer (25 mM Tris-
Base, 192 M glycine, 0.1% SDS, 20% methanol). The efficiency of the transfer was assessed 
by lack of Coomassie blue coloration of the gel after blotting, and Ponceau staining of the PVDF 
membrane (Coomassie blue solution and Ponceau solution for protein detection: Sigma, St. 
Louis, MO, USA).  
Membranes were blocked for 1.5 hours at room temperature in 3% defatted milk 
dissolved in T-TBS (0.2% Tween 20; 20 mM Tris-HCl pH 7.5; 500 mM NaCl) and incubated 
O/N at 4°C with primary antibodies. The rabbit polyclonal anti-acetyl histone H3 (lys14) 
antibody (final concentration 0.7 μg/mL, 07-353, Merck Millipore, Temecula, CA, USA) and 
rabbit polyclonal anti-actin A2066 (normalization, final concentration of 0.07 μg/mL, Sigma 
Chemical, St. Louis, MO, USA), were diluted in 3% defatted milk T-TBS.  
The following day, membranes were washed three times with 3% defatted milk T-TBS 
and incubated for 2 hours with the secondary antibody anti-rabbit IgG peroxidase (Dako, 
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Agilent Technologies, Santa Clara, CA, USA) at the final concentration of 0.0625 μg/mL in 
3% defatted milk T-TBS.  
Protein bands, respectively at 17 kDa (H3K14ac) and 42 kDa (actin), were detected by 
peroxidase reaction according to the manufacturer's protocol using a chemioluminescence 
procedure (ECL-Plus Western blotting Detection Reagents, GE-Healthcare Bio-Science, Italy) 
and visualized on X-ray films (BioMax Light, Kodak Rochester, NY, USA).  
 
 
3.6 CHROMATIN IMMUNOPRECIPITATION ASSAY  
 
Chromatin immunoprecipitation (ChIP) is a powerful method to identify regions of the 
genome associated with some specific proteins, such as histone subunits or post-translational 
modifications. 
The assay was performed following the complete protocol provided by the Magna 
ChIPTM G Tissue Kit (#17-20000, Merck Millipore, Temecula, CA, USA). All the reagents 
were provided by the kit. Some conditions for ChIP were settled-up for better results: cross-
link time, sonication, antibody amount. 
Based on the Western blot results (for details see “Results” section), 40-50 mg of Cll of 
P9 animals, both hyperbilirubinemic (jj) and non-hyperbilirubinemic (JJ/Jj) ones were 
homogenized and cross-linked with 1% formaldehyde for 5 min, RT. The excess formaldehyde 
was quenched by addition of glycine and samples were resuspended in tissue lysis buffer.  
Chromatin was sheared to an average size of 100-400 base pairs by sonication (Sonopuls 
HD 3100, Bandelin, Germany), keeping the sample in ice to avoid overheating. The sonication 
parameters were: power 50%, 18 cycles of 15 seconds per cycle and 105 seconds of pause 
between each cycle.  
Chromatin fragment size was evaluated by loading the sample on a 2% agarose gel with 
a 100 bp marker, after incubation with RNase A for 30 min at 37°C, with proteinase K for 2 
hours at 62°C, then 10 min at 95°C.  
Protein-DNA complexes were immune-precipitated with 5 μL of the rabbit polyclonal 
anti-acetyl histone H3 (lys14) antibody (07-353, Merck Millipore, Temecula, CA, USA). Half 
  MATERIALS AND METHODS 
  
 
32 
 
part of the sample was used as a negative control by the incubation with 5 μL of the anti-rabbit 
IgG peroxidase antibody (Dako, Agilent Technologies, Santa Clara, CA, USA), while 1% of 
the same sample was used as input DNA.  
G magnetic beads were added in order to capture only the chromatin/antibody complex 
leaving un-bound molecules in solution. 
After washing the beads using the magnetic rack (LSKMAGS08 Pure ProteomeTM 
Magnetic Stand, Merck Millipore, Temecula, CA, USA), protein-DNA crosslink was reversed 
incubating the sample with proteinase K at 62°C for 2 hours, followed by incubation at 95°C 
for 10 minutes. 
Beads were separated, the supernatant containing proteins was removed, DNA purified 
and stored at -20°C until use.  
Western blot and Real-Time quantitative PCR (RT-qPCR) were performed to verify the 
ChIP procedure success. 
 
3.6.1 WESTERN BLOT FOR ChIP CONTROL 
 
Western blot (described in detail above) was performed to verify the success of the ChIP 
assay. It was performed on three 20 μL samples collected during the ChIP procedure: one 
incubated with rabbit polyclonal anti-H3K14ac antibody, one incubated with the anti-rabbit 
IgG peroxidase antibody (negative control), both collected before the cross-link reversal, and 
the beads obtained after the incubation of samples and antibodies and the subsequent reverse 
cross-link procedure. 
The membrane was incubated with the antibody of interest (anti-H3K14ac) and then with 
the anti-rabbit IgG peroxidase. The goal was to detect the band at 17 kDa in the 
immunoprecipitated sample, but not in the negative control and beads. 
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3.6.2 RT-qPCR FOR ChIP CONTROL 
 
RT-qPCR is the second possible control to verify the success of the ChIP assay. 
The conditions for RT-qPCR were suggested by the kit Magna ChIPTM G Tissue Kit (#17-
20000, Merck Millipore, Temecula, CA, USA) used for ChIP and rearranged, as reported 
below. 
As the H3K14ac binding sites on the DNA were never reported before in literature in this 
specific tissue and animal model, different primers were tested, also following some indications 
provided by the kit used for ChIP. 
The samples were diluted in a working solution of Sso AdvancedTM Universal SYBR® 
Green Supermix (BioRad, Hercules, CA, USA) and primer mix for a total volume of 25 μL. 
Parameters for the PCR reaction are reported in the table below. 
Cycle Step Temp Time Cycles 
Initial Denaturation 94°C 10 min 1 
Denaturation 94°C 20 sec 
Repeated 50 times 
Anneal and Extension 60°C  1 min 
Melting 55°C 1 min 1 
Melting 55°C 10 sec Repeated 80 times 
Infinite hold 4°C ∞  
 
Table 3-2. RT-qPCR parameters for the amplification of the genomic sequence of interest. 
 
Primers were designed using the software Beacon Designer 4.0 (Premier Biosoft 
International, Palo Alto, CA, USA) on rat sequence available in GenBank.  
 
Table 3-3. Primer sequences designed for the analysis. 
Gapdh: glyceraldehyde 3-phosphate dehydrogenase. Actin: beta actin. MyoD: myogenic differentiation. cMyc: v-myc avian 
myelocytomatosis viral oncogene homolog. 
Gene Primer sequence: Forward Primer sequence: Reverse 
Ampl. 
Lenght 
Gapdh CTCTCTGCTCCTCCCTGTTC CACCGACCTTCACCATCTTG 87 
Actin GGCATTGCTGACAGGATG TGGAAGGTGGACAGTGAG 137 
MyoD GTCTCTCAGCCTCTTTCGGT AGCGGCTGTAGAAATCAGGTC 108 
cMyc CCCAAAAAAAGGCACGGAA TATTGGAAATGCGGTCATGC 89 
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1% input, immunoprecipitated samples, and negative control were added and RT-qPCR 
performed in an i-Cycler IQ (Bio-Rad Laboratories, Hercules, Ca, USA). 
The final analysis was performed using the fold enrichment method (relative 
quantification by the modified ΔΔCt method) 206,207. 
 
 
3.7 ChIP-SEQ 
 
All the samples obtained by ChIP assay were quantified using Quant-iTTM PicoGreen ® 
dsDNA Reagent and Kits (Thermo Fisher Scientific, Waltham, MA, USA), an ultrasensitive 
fluorescent nucleic acid stain able to detect and quantitate small amounts of dsDNA (double 
strand DNA), according to manufacturer’s instruction. 
 
3.7.1 DNA LIBRARY PREPARATION 
 
Two different kits were tested in order to obtain good quality and quantity DNA libraries 
from ChIP DNA. The kits were: the NEBNext® UltraTM II DNA Library Prep Kit for Illumina® 
(E7645, New England BioLabs®Inc, MA, USA), and the NEXTflexTM ChIP-Seq Kit (Illumina 
Compatible) (5143-01, Bioo Scientific Corp, TX, USA). Due to the better quality and the higher 
final concentration of the DNA libraries obtained, the first one was used in this thesis’s work.  
Briefly, 10 ng of fragmented DNA underwent to end repair, 5’ phosphorylation, dA-
tailing, adaptor ligation and Uracil excision. 
The cleanup of Adaptor-ligated DNA was performed without size selection using 
Agencourt AMPure XP magnetic beads (Beckman Coulter Life Sciences, CA, USA). 
PCR enrichment of adaptor-ligated DNA followed the protocol parameters reported in 
the table below:  
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Cycle Step Temp Time Cycles 
Initial Denaturation 98°C 30 sec 1 
Denaturation 98°C 10 sec 
Repeated 10 times 
Anneal and Extension 65°C  75 min 
Final Extension 65°C 5 min 1 
Infinite hold 4°C ∞  
 
Table 3-4. PCR enrichment of Adaptor-Ligated DNA parameters. 
 
 
 
Figure 3-2. DNA library preparation flowchart. 
End repair, 5’ phosphorylation, dA-Tailing, Adaptor Ligation, Uracil Excision, and PCR enrichment are well represented in 
the scheme taken from the datasheet of the NEBNext® UltraTM II DNA Library Prep Kit for Illumina® (E7645, New England 
BioLabs®Inc, MA, USA). 
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After the PCR cleanup, the libraries were quantified using the PicoGreen fluorescent dye, 
as reported above, and stored at -20°C until use. 
 
3.7.2 LIBRARIES DENATURATION AND DILUTION 
 
The libraries were denatured and diluted to a final concentration of 15 pM with 10% PhiX 
(Illumina) control. Paired-end sequencing was performed using the MiSeq reagent kit v3 2x150 
in the Illumina® MiSeq® system (Illumina, San Diego, CA, USA).  
 
 
 
 
 
 
 
 
 
Figure 3-3. Illumina® MiSeq® system (figure taken from the brochure of the machinery). 
 
 
 
3.8 COMPARATIVE ANALYSIS OF THE DNA 
SEQUENCES OF jj AND CONTROLS 
 
Reads from libraries of jj and control animals were mapped to the Rattus norvegicus (rn4) 
genome using bowtie2 208.  
Duplicate reads were filtered. The quality of the sequences was evaluated using fastQC, 
a quality control tool for high throughput sequence data (available online at 
http://www.bioinformatics.babraham.ac.uk/projects/fastqc/).   
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Peaks were called using MACS2 209, which used the pool of libraries obtained from 
control animals, and then annotated using HOMER, a software for motif discovery and next-
generation sequencing analysis 210. 
The statistical analysis used the cut-off reported below and q-values were calculated from 
p-values using Benjamini-Hochberg procedure:  
 q-value cut-off for narrow/strong regions: 5.00e-02 
 q-value cut-off for broad/weak regions: 1.00e-01. 
 
The web-based tool GENECODIS (http://genecodis.cnb.csic.es/), capable of integrating 
diverse biological information, was used to interpret the gene lists obtained with the ChIP-Seq 
and to divide them in the biological processes in which they are involved in.  
 
 
3.9 VALIDATION OF SELECTED GENES 
 
After the ChIP-seq, the quantitative analysis of a limited number of interesting genes was 
performed by RT-qPCR. 
Genes were selected following these parameters: 
 Localization of the peak detected closer to the promoter or transcriptional starting 
site (TSS), the exon or the intron; 
 Control of regulatory mechanisms of cellular differentiation, neuronal fibers 
maturation, and apoptosis. 
 
3.9.1 RNA EXTRACTION AND RETROTRANSCRIPTION 
 
The mRNA expression of genes of interest was analyzed by quantitative RT-PCR. 
Total RNA of Cll of P9 jj and JJ/Jj animals was extracted using Eurogold RNA Pure 
reagent (Euroclone, Milan, Italy). 
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Retrotranscription of total RNA (1μg) was performed with High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Monza, Italy) according to the manufacturer’s 
instructions. The reaction was run in a thermal cycler (Gene Amp PCR System 2400, Perkin-
Elmer, Boston, MA, USA) at 25°C for 5 min, 37°C for 120 min, and 85°C for 5 min. the final 
cDNA was stored at 20°C until use. 
3.9.2 RT-qPCR 
 
For RT-qPCR, primers were designed using the Beacon designer 8.1 software (Premier 
Biosoft International, Palo Alto, CA, USA) on rat sequences available in GenBank (see table 
3.5).  
 
Table 3-5. Primer sequences designed for the analysis. 
Anxa5: annexin A5. Shox2: short stature homeobox 2. Neurod1: neuronal differentiation 1. Wnt4: wingless-type MMTV 
integration site family, member 4. Wnt5a: wingless-type MMTV integration site family, member 5a. Casp9: caspase 9. Sema5a: 
semaphorin 5a. Cdk1: cyclin-dependent kinase 1. Bcl2l11: Bcl-2-like 11. Ctnna1: catenin alpha 1. Gadd45b: growth arrest and 
DNA-damage-inducible, beta. Gadd45g: growth arrest and DNA-damage-inducible, gamma. Sod2: superoxide dismutase 2. 
Rdh10: retinol dehydrogenase 10. Arf6: ADP-ribosylation factor 6. Cdkn2b: cyclin-dependent kinase inhibitor 2b. Lama5: 
laminin subunit alpha 5. Nrg1: neuregulin 1. 
Gene Primer sequence: Forward Primer sequence: Reverse 
Ampl. 
Lenght 
Anxa5 TAATGACCAAAGCTGTCTCG TTGATTGACAGCACTTCCAA 200 
Shox2 TGAAGCTTGTAGAGTTGCAC TCACGTTGCAATGACTATCC 80 
Neurod1 AACGAATCCACTGTGCTTAC TTCTTCCAAAGGCAGTAACG 133 
Wnt4 AGTGGAGATCTGGAGAAGTG ACGTCTACAAAGGACTGTGA 128 
Wnt5a CAGATGTAGCCTGTAAGTGC CGCTGTCATACTTCTCCTTG 117 
Casp9 TGCTAAGAAAATGGTCACGG ATCCATCTGTGCCATAGACA 143 
Sema5a CAGATTGTGAGGAAATGGCA AATGTGTGTGTAATGGAGGC 102 
Cdk1 CTTGGACTTGCTCTCGAAAA CCAAGTCGTCAAAGTATGGG 92 
Bcl2l11 TGTGGACTGAACTTACCTGT CTCTAGAGCTTCAGTGAGCT 141 
Ctnna1 CGAGAAGGAGGTTAAGGAGT GCTTCACGCCTTCTTCATTA 110 
Gadd45b GCCAAACTGATGAATGTGGA TGGATCAGGGTGAAGTGAAT 107 
Gadd45g GAAAGCATTGCACGAACTTC TATGTCGCCCTCATCTTCTT 148 
Sod2 AAGGATGGATGGAGTGGTAG ATGTCACTCCTCTCCGAATT 131 
Rdh10 ACCTATACCTGTGATGTGGG GAAGGTGATGTCCAGAAACC 124 
Arf6 ACCTCTTTCAATTGCCACTC AAGGGGAACAAAGAAAACCC 91 
Cdkn2b TGAAGTGGGTTTATGCACTG TCACCGTTTAGCAGAGATCT 132 
Lama5 ATGTGCTCATCAAGTTTGCT CTCCAAACAATCCCTCTTGG 125 
Nrg1 AGCCACAAACAACAGAAACT AAAGTTTTCTCCTTCTCCGC 109 
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The reaction was performed in a final volume of 15 μL in an iCycler iQ thermocycler 
(Bio-Rad Laboratories, Hercules, CA, USA). Briefly, 25 ng of cDNA and the corresponding 
gene-specific sense and anti-sense primers (250 nM each) were diluted in the SSo Advance 
SYBER green supermix (Bio-Rad Laboratories, Hercules, CA, USA). Amplification protocol 
is reported in the table below: 
Cycle Step Temp Time Cycles 
Initial Denaturation 95°C 3 min 1 
Denaturation 95°C 20 sec 
Repeated 40 times Anneal and Extension 60°C  20 sec 
Final Extension 72°C 30 sec 
Infinite hold 4°C ∞  
 
Table 3-6. RT-qPCR parameters for the amplification of the genomic sequence of interest. 
 
 
Melting curve analysis was performed to assess product specificity. The relative 
quantification was made using the iCycler iQ Software, version 3.1 (Bio-Rad Laboratories, 
Hercules, CA, USA) by the Pfaffl modification of the ΔΔCT equation (CT: cycle number at 
which the fluorescence passes the threshold level of detection), taking into account the 
efficiencies of the individual genes 206,207.  
The results were normalized to the chosen housekeeping genes and the initial amount of 
the template of each sample was determined as relative expression vs. one of the samples chosen 
as reference. 
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3.10 HISTOLOGY 
 
Immediately after animals sacrifice by decapitation, the entire brain was fixed in formalin 
solution 4% buffered (4% of formaldehyde 37%, 33 nM NaH2PO4, 46 mM Na2HPO4), then 
embedded in paraffin. 
Sagittal sections of the brain at 3-5 μm of thickness were obtained by the use of the 
microtome (Microm-hm 340e- BioOptica, Milan, Italy), affixed on the glass slides and dried at 
60°C for 1 hour.  
Representative sections presenting the complete panel of all the regions of interest were 
subjected to histochemical procedures in order to assess cell damage. 
 
3.10.1 HEMATOXYLIN – EOSIN 
 
Hematoxylin and eosin stain (H&E) is the most common staining technique in 
histopathology. The combination of the two dyes is useful for the evaluation of cell and tissue 
morphology. Hematoxylin is a dark blue/violet color that is basic/positive and binds to 
basophilic substances, such as DNA in the nucleus and RNA in the ribosomes and endoplasmic 
reticulum. Eosin is a red/pink color that is acidic /negative, so it binds to acidophilic substances, 
such as positively charged aminoacid side chains in the cytoplasm. 
Sections of rat brain were stained with the H&E protocol, performed by a Leica ST5020 
Multistainer (Leica Microsystem, Milan, Italy) in order to assess the presence of apoptosis, 
necrosis, microgliosis, edema, and cell loss. Staining was performed as follow: Xylol 2x5’; 
Ethanol 2x4’; H2O 1x3’; Hematoxylin 12’; H2O 2x6’; Eosin 1x1,30’; Ethanol 2x3’; Xylol 1x3’ 
plus 1x2’. Histology was read by two independent pathologists, blinded to experimental design 
and treatment groups at the Department of Pathological Anatomy of the local Teaching 
Cattinara Hospital. Pictures were collected by a D-Sight plus image digital microscope & 
scanner (Menarini Diagnostics, Firenze, Italy). 
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3.10.2 CRESYL VIOLET STAINING (NISSL STAINING) 
 
Cresyl Violet Staining is a useful method to identify the neuronal structure, staining the 
Nissl substance in the cytoplasm of neurons. The basic aniline dye is used to stain RNA blue: 
the Nissl substance (endoplasmic reticulum) appears dark blue due to the staining of ribosomal 
RNA.  
After deparaffinization procedure (Xylol 3x5’; 100% Ethanol 2x2’; 95% Ethanol 2x2’; 
80% Ethanol 1x2’; 70% Ethanol 1x2’; H2O 2x5’), brain sections affixed on the slice were 
incubated for 1h in pre-filtrated 0.1% Cresyl Violet Solution (0.1% Cresyl Violet powder and 
10 drops of glacial acetic acid in mQ H2O).  
Slices were washed in H2O twice, quickly destained in 75% Ethanol, and differentiated 
in 95% Ethanol (95% Ethanol, 5% Chloroform, 3 drops of glacial acetic acid). 
After dehydration procedure (100% Ethanol 2x5’; Xylol 2x5’), slices were mounted 
(Eukitt 03989, SIGMA Aldrich) and observed under optical microscope. 
 
 
3.11 STATISTICAL ANALYSIS  
 
Fold and percent changes were calculated based on corresponding controls. All data are 
expressed as mean ± SD. 
Data were analyzed using GraphPad InStat for Windows (GraphPad Software, Inc, La 
Jolla, CA, USA). Statistical significance was evaluated by the unpaired two-tailed Student’s t-
test, performed based on unequal variance as appropriate. This parametric test was chosen to 
evaluate the difference between the jj and the control in the analysis of the acetyl-histone H3 
(lys14), considered for each age. 
ANOVA test, Tukey-Kramer multiple comparison tests, was used to compare different 
post-natal ages in the analysis of TSB level and cerebellar weight.  
In both tests, a p-value lower than 0.05 was considered statistically significant. 
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4 RESULTS 
 
 
The original goal of my study was to investigate the involvement of histone H3 
acetylation in bilirubin-induced encephalopathy, using the Gunn rats, identifying all the genes 
that are regulated by this epigenetic mechanism and possibly implicated in this pathology, and 
evaluating its possible effect on the phenotype. 
 
 
4.1 CHARACTERIZATION OF THE ANIMAL MODEL 
 
The colony was characterized by monitoring the landmark features of the Gunn strain: 
the TSB levels and cerebellar hypoplasia. 
                                                                                                                                                                                                                                                                                                                                                                                                                                        
4.1.1 TOTAL SERUM BILIRUBIN MEASUREMENT  
 
As Figure 4.1 shows, in hyperbilirubinemic (jj) animals TSB levels rise rapidly after birth. 
At P2, the TSB was about 11 mg/dL and reached the peak level at P17 (15.1 ± 2.68 mg/dL). 
Thereafter, in older animals, TSB decreased to the values of around 7.4 ± 2.06 mg/dL, which 
are typical and stable during the adulthood.  
Moreover, after genotyping (Figure 4.2) allowing to distinguish heterozygous (Jj) from 
homozygous wild-type (JJ) animals, no detectable differences in TSB level were noticed, with 
a constant value of around 0.5 mg/dL all lifelong in both Gunn genotypes.  
At every post-natal age, the values were statistically different (p ≤ 0.001) if compared to 
the not icteric Gunn rats. 
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Figure 4-1. Comparison of TSB in different Gunn rat genotypes at 4 post-natal ages. 
 A) TSB concentration was expressed in mg/dL. P: post-natal age in days. OLD = more than 60 days old. Anova test, taking 
into consideration a possible variability due to the animal maturation, was applied to this analysis. The results were expressed 
as mean ± SD of 10-30 animals for each age and genotype. *** and ### < 0.001 vs. JJ and Jj of the same age, respectively. B) 
JJ/Jj vs. jj serum appearance was represented in the image on the right upper side.  
 
 
 
 
 
 
 
 
Figure 4-2. Representative genotyping results in JJ, Jj, and jj Gunn rats. 
Two bands of about 230 bp and 80 bp are present in the homozygous wild-type animals (line 1), due to the presence of the 
BstNI restriction site. Three bands are visible in the heterozygous animals (line 5), while only one band of about 320 bp is 
visible in the homozygous hyperbilirubinemic Gunn rat (lines 2-4). 
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4.1.2 CEREBELLAR GROWTH EVALUATION 
 
The effect of high levels of bilirubin is clearly manifested in the hypoplasia of the 
cerebellum in jj animals.  
Cerebellar weights in jj and non-hyperbilirubinemic littermates (both JJ and Jj) were 
identical at P2 but started to show a detectable difference (around 10%) since 9 days after birth. 
Cerebellar growth resulted significantly impaired in jj animals at P17 and almost completely 
arrested in adult age. The cerebellar weight was about 30% lower in jj if compared to controls 
at P17 (p≤0.001), and 45% lower in jj older animals (p≤0.001). 
Importantly, no differences in cerebellar weight were observed between JJ and Jj animals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-3. Comparison of cerebellum weight in different Gunn rat genotypes at 4 post-natal ages.  
Cerebellar weight was expressed in g/animal. P: post-natal age in days. OLD= more than 60 days old. Anova test, taking into 
consideration a possible variability due to the animal maturation, was applied to this analysis. The results were expressed as 
mean ± SD of 10-30 animals for each age and genotype. *** and ### < 0.001 vs JJ and Jj of the same age, respectively.  
 
  RESULTS 
 
 
45 
 
These results, together with the TSB data, confirm that our strain of Gunn rat possesses 
the typical characteristics of the animal model for neonatal hyperbilirubinemia, Crigler-Najjar 
type I syndrome and kernicterus. Moreover, because JJ and Jj are identical in both parameters, 
both genotypes were used as controls for the following analyses. This allowed also an 
optimization of the use of the littermates, in agreement with the ethical rules. 
 
  
4.2 HISTONE H3 ACETYLATION 
 
The screening of the levels of the acetyl-histone H3 (lys 14) (H3K14ac) was performed 
in different brain regions (Cx, Cll, Hip, SC, IC) of the Gunn rat at four post-natal ages (P2, P9, 
P17, adulthood) by Western blot.  
The specificity of the antibody was first checked running one sample on 12% 
polyacrylamide gel. The H3K14ac was recognized as a single, defined band detectable at 17 
kDa, the expected molecular weight. No other bands were detected. For such reason, the 
antibody was considered suitable not only for the analysis of the levels of H3K14ac but also 
for the immunoprecipitation of the Gunn rat brain samples.  
 
 
 
 
 
Figure 4-4. Control of the specificity of the anti-H3K14ac antibody in rat brain. 
Line 1: molecular weight label; line 2: Gunn rat brain sample. No other bands were detected. 
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At P2, no significant differences in the level of H3K14ac jj animals compared to controls 
(red line) were observed for all brain regions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-5. H3K14ac in the brain of the 2-days old jj Gunn rat. 
The H3K14ac level was expressed as fold vs. the level in controls (red line). Actin was used to normalize the results. Cx: 
cerebral cortex, Cll. Cerebellum, SC: superior colliculi, IC: inferior colliculi, Hip: hippocampus. The results were expressed as 
mean ± SD of 3-6 animals for each age and genotype. T-test was applied to this analysis. 
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At P9, the level of the H3K14ac was significantly increased in Cll (1.65±0.54 fold, 
p<0.05), Hip (1.75±0.49 fold, p<0.05), and in IC (2.64±0.77 folds, p<0.01) in jj animals 
compared to control pups (red line). No significant differences were reported for Cx and SC.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-6. H3K14ac in the brain of 9-days old Gunn rats. 
The H3K14ac level was expressed as fold vs. the level in controls (red line). Actin was used to normalize the results. Cx: 
cerebral cortex, Cll: Cerebellum, SC: superior colliculi, IC: inferior colliculi, Hip: hippocampus. The results were expressed as 
mean ± SD of 3-6 animals for each age and genotype. T-test was applied to this analysis. * <0.05; ** < 0.01. 
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By contrast, at P17 the H3K14ac displayed no significant differences in Cx, Hip, and SC 
of jj animals if compared to the control pups. While, the level of the Histone H3 acetylation 
significantly decreases in Cll (0.58±0.27 fold, p<0.05) and IC (0.67±0.18 fold, p<0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-7. H3K14ac in the brain of 17-days old Gunn rats. 
The H3K14ac level was expressed as fold vs the level in controls (red line). Actin was used to normalize the results. Cx: 
cerebral cortex, Cll: Cerebellum, SC: superior colliculi, IC: inferior colliculi, Hip: hippocampus. The results were expressed as 
mean ± SD of 3-6 animals for each age and genotype. T-test was applied to this analysis. * <0.05.  
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In jj older animals, only Cx showed a very significant reduction of H3K14ac (0.29±0.10 
fold, p<0.01) if compared to the age-matched controls. All the other brain regions showed no 
significant differences. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-8. H3K14ac in the brain of older (>P60) Gunn rats. 
The H3K14ac level was expressed as fold vs the level in controls (red line). Actin was used to normalize the results. Cx: 
cerebral cortex, Cll: Cerebellum, SC: superior colliculi, IC: inferior colliculi, Hip: hippocampus. The results were expressed as 
mean ± SD of 3-6 animals for each age and genotype. T-test was applied to this analysis. ** <0.01. 
 
Altogether the data we obtained revealed for the first time a modulation of the acetylation 
in the brain of the hyperbilirubinemic Gunn rat. Moreover, this modulation depends on the brain 
region and post-natal age considered. 
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4.3 ChIP ASSAY 
 
To link directly the effect of hyperbilirubinemia on the H3K14ac with the genes 
controlled by this epigenetic mechanism, the 07-353 antibody anti-H3K14ac was used also for 
the chromatin immunoprecipitation. 
Cerebella from P9 animals, both jj and controls, were chosen for this analysis because: 
a) cerebellum presented a significant modulation of the H3K14ac level (H3K14ac 
increased at P9, while decreased at P17); 
b) this CNS region is the hallmark of the hyperbilirubinemic Gunn rat, as 
documented by the wide existing literature; 
c) because it guaranteed a sufficient amount of tissue for the planned analysis.  
The ChIP technique was settled up for the rat brain samples starting from the protocol 
provided by the Magna ChIPTM G Tissue Kit (#17-20000, Merck Millipore, Temecula, CA, 
USA).  
The sonication parameters to shear the chromatin were carefully refined trying different 
conditions. As shown in the figure 4-9 A, three different amount (10 mg: lines 3-5, 20 mg: lines 
6-8, 40-50 mg: lines 9-11) of Cll were sonicated at three different settings, maintaining the same 
power at 50%: (a) 6 cycles of 15 seconds per cycles and 105 seconds of pause between each 
cycle (lines 3, 6, 9), (b) 12 cycles of 15 seconds per cycles and 105 seconds of pause between 
each cycle (lines 4, 7, 10), (c) 18 cycles of 15 seconds per cycles and 105 seconds of pause 
between each cycle (lines 5, 8, 11). Finally the ideal tissue amount (40-50 mg) and sonication 
parameters (power 50%, 18 cycles of 15 seconds per cycles and 105 seconds of pause between 
each cycle) allowed to obtain chromatin fragments to an average size of 100-400 base pairs. 
Notably, in addition to Cll, a second abundant brain region was used in this step: the 
cerebral cortex. 
As shown in Figure 4-9 B, the Cx resulted over-fragmented using the same sonication 
protocol settled up for the Cll. The expected chromatin fragments for Cx (Figure 4-9 C) were 
obtained by decreasing the number of sonication cycles (power 50%, 10 cycles of 15 seconds 
per cycles and 105 seconds of pause between each cycle), revealing that the composition of 
tissue may influence the sonication efficiency. 
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Figure 4-9. Evaluation of chromatin shearing conditions. 
(A, B, C) Line 1: 100 bp marker. (A) Line 2: control, not-sonicated sample. Lines 3-5: 10 mg Cll. Lines 6-8: 20 mg Cll. Lines 
9-11: 40-50 mg Cll. Sonication parameters: a (lines 3, 6, 9); b (lines 4, 7, 10); c (lines 5, 8, 11). Best sonication condition 
reported in line 11. (B) Line 2: Cll. Line 3: Cx. Same sonication parameters sheared Cll and Cx chromatin differently. (C) 
Lines 2 and 3: Cll. Lines 4 and 5: Cx. Same Cll and Cx fragments size were obtained with different sonication parameters.  
 
 
The successful of the ChIP procedure was evaluated by Western blot and RT-qPCR. 
The Figure 4-10 A showed the expected band at 17 kDa in the H3K14ac-sample, but not 
in the negative control, as expected. The 17kDa band was unexpectedly detected also in the 
beads-sample suggesting that the H3K14ac protein was still present, probably retaining part of 
the DNA. This trouble was subsequently discovered to be due to the addition of an incorrect 
amount of the proteinase K, thus unable to digest proteins. Bigger bands were detected also at 
30 kDa and 55-70 kDa and they could be recognized as the antibody used for the ChIP and/or 
other non-specific proteins. 
After correcting the amount of the proteinase K used for the digestion of the proteins, a 
very good result was obtained as reported in the Figure 4-10 B. In the figure a band at 17 kDa 
was detected only in the H3K14ac-sample, but not in the negative control and in the beads, 
suggesting that all the proteins present in the samples were correctly and completely digested 
by the proteinase K. 
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Figure 4-10. Western Blot control for the success of ChIP.  
Negative control (NEG CTRL), H3K14ac and beads samples were reported. In evidence the molecular weight of 17 kDa, 30 
kDa and 55-70 kDa where bands were detected.  
 
 
RT-qPCR was performed on the purified DNA sample obtained from ChIP. 
As a first attempt, we made a RT-qPCR using a cMyc promoter primer and a MyoD 
primer, as suggested by the ChIP kit. Unfortunately, we weren’t able to obtain the expected 
enrichment (around of 100 folds between the immune-precipitated sample and the whole not-
immuno-precipitated genomic DNA). 
Based on our experience in the field of hyperbilirubinemia, we tested two new primers: 
actin and GAPDH. As showed in Figure 4-11 A and B, the results obtained were as expected 
for an appropriate ChIP procedure (for actin the signal in the H3K14ac-sample was about 99 
folds higher than in the negative control, for GAPDH was about 150 folds higher). By this 
results, we do not only demonstrated the success of the ChIP on Gunn rat brain samples, but 
we also individuated two primers that could be used as controls for ChIP assay in bilirubin 
encephalopathy. 
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Figure 4-11. RT-qPCR control for the success of ChIP.  
(B and C) Results obtained using actin and GAPDH primers: in both cases, the primers could be considered as good controls 
for ChIP. 
 
Once verified the success of the ChIP, the DNA of the cerebella samples from P9 animals 
was purified for the following sequencing steps. 
 
 
4.4 COMPARATIVE ANALYSIS OF THE DNA 
SEQUENCES OF jj AND CONTROLS 
 
Two DNA libraries were prepared from a pool of three Cll from jj and three Cll from 
control ChIP DNA. In order to obtain 10 ng of libraries, the pools were prepared mixing the 
samples taking in consideration their respective concentration. The concentrations of the 
libraries obtained were: 54.2 nM for jj and 75.4 nM for controls. 
An equal concentration (10 nM) of both (jj and ctrl) libraries were submitted to 
sequencing. After the sequencing, we obtained: 12744 reads for the jj pool and 15908 reads for 
the control pool. A good overall quality for both the runs was obtained.  
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The comparative analysis of the pool of libraries of 3 jj animals vs. the control resulted in 
the annotation of 170 significant peaks. This analysis purposed to reveal the sequences of the 
DNA in which hyperbilirubinemia induced chromatin opening via H3K14 acetylation. 
More than the 87% of the peaks was intergenic, mostly located on satellite region or LINE 
(long interspersed nuclear element) region of the DNA. A very few percentage was detected in 
the other regions of the DNA. Only 6.5% of the peaks was found to be located in the intron 
region of the DNA, 4.7% of the peaks in the promoter – TSS (Transcription Start Site) region 
of the DNA, and the 0.6% of the peaks in the exon region of the DNA. 1.2% of the peaks was 
located in non-coding regions of the DNA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-12. Peak annotation of the jj compared to the control. 
List of the significant peaks divided according to the location into specific regions of the DNA: Exon, Intergenic, Intron, Non-
coding, Promoter-TSS. 
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To identify the portion of the chromatin de-activated (condensed) in hyperbilirubinemic 
rats, the peaks obtained from hyperbilirubinemic samples were subtracted to the peaks of 
control animals. 3311 significant peaks present only in normobilirubinemic conditions were 
counted.  
Despite the high percentage (37.2 %) of peaks located in the intergenic DNA, the 25.6% 
of the peaks was located on the promoter-TSS region of the DNA. 17.4% of the sequences was 
located on introns and the 12.8% was located in exons. A very low percentage (0.2%) of the 
peaks was located in non-coding regions of the DNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-13. Peak annotation of the control compared to the jj rat. 
List of the significant peaks divided according to the location into specific regions of the DNA: 3’UTR (Un-Translated 
Regions), 5’UTR, Exon, Intergenic, Intron, Non-coding, Promoter-TSS (Transcriptional Start Site), TTS (Transcriptional 
Termination Site). 
 
Once the peaks were analyzed, we were able to obtain a list of single sequences both in 
jj and controls.  
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A gene ontology analysis (GeneCodis: http://genecodis.cnb.csic.es/) was performed both 
for the list of sequences in jj vs. controls and in controls vs. jj, in order to assemble the genes 
considering their biological function. After choosing not to consider sequences present on non-
coding regions of the DNA, the overall list of sequences was divided into two groups: one 
included sequences located on exon, intron, promoter-TSS (Transcriptional Start Site ) and TTS 
(Transcriptional Termination Site) regions of the DNA, the other included sequences located in 
intergenic regions of the DNA.  
The analysis of the sequences located in exon, intron and promoter-TSS portions of the 
DNA in jj vs. control identified genes involved in regulatory pathways of the development of 
the nervous system, such as brain morphogenesis, development of axons and dendrites, and 
synapsis generation, as well as pathways that regulate the physiological cellular homeostasis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-14. Gene ontology analysis in jj vs. control. 
 Sequences located on exon, intron and promoter-TSS regions of the DNA in jj vs. control were grouped considering their 
biological functions. Number of genes and description of the biological processes were reported. 
 
GENE BIOLOGICAL PROCESS
3
somatic diversification of immunoglobulins; keratan sulfate biosynthetic process; sulfur 
metabolic process; N-acetylglucosamine metabolic process; granulocyte differentiation
1
regulation of circadian rhythm; regulation of protein catabolic process; protein import 
into nucleus, translocation
1
regulation of synapse structural plasticity; radial glia guided migration of Purkinje cell; 
brain morphogenesis; prepulse inhibition; dendrite morphogenesis; axonogenesis
1
positive regulation of peptidyl-threonine phosphorylation; regulation of glycolysis; 
regulation of fatty acid metabolic process; glycogen metabolic process;  regulation of 
protein kinase activity; regulation of catalytic activity; protein kinase cascade
1
retinoic acid biosynthetic process; nose development; neural crest cell development; 
embryonic viscerocranium morphogenesis; ear development; retinol metabolic process; 
retinal metabolic process; embryonic organ development; embryonic forelimb 
morphogenesis; visual perception; organ morphogenesis
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Genes that are involved in the activation of CNS developmental pathways and cellular 
differentiation were also identified among sequences located in intergenic regions of the DNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-15. Gene ontology analysis in jj vs. control. 
Sequences located in intergenic regions of the DNA were grouped considering their biological function. Number of genes and 
description of the biological processes were reported. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GENE BIOLOGICAL PROCESS
6 multicellular organismal development, cell differentiation
3 cell adhesion
3 forebrain development
3 nervous system development
3 response to organic cyclic compound
3 nucleosome assembly
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The analysis of the sequences located in exon, intron, promoter-TSS, TTS and UTR 
portions of the DNA in control vs. jj identified several groups of genes that are involved in a 
complex regulation of different functions.  
A part 40% of genes involved in different signaling pathways (Figure 4-16) indicated 
more in detail in Figure 4-17, a complex developmental and differentiation pattern was 
controlled by 22% of genes. Cellular growth and proliferation were regulated by 13% of genes, 
as well as cell death process in which 9% of genes were implicated. Cellular migration was also 
present, with 3% of genes involved in. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-16. Gene ontology analysis in control vs. jj.  
Percentage of genes grouped by biological function. Sequences reported are located on exon, intron, promoter-TSS, TTS and 
UTR regions of the DNA.  
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Figure 4-17. Gene ontology analysis in control vs. jj.  
Number of genes and description of the biological processes were reported. Sequences reported are located on exon, intron, 
promoter-TSS, TTS and UTR regions of the DNA.  
NUMBER OF 
GENES
BIOLOGICAL PROCESS
124
regulation of cysteine-type endopeptidase activity involved in apoptotic process; regulation of 
apoptotic process; regulation of neuron apoptosis
8 circadian rhythm
302
actin cytoskeleton organization; aging; anatomical structure development; angiogenesis; 
anterior/posterior pattern specification; axon guidance and axonogenesis; central nervous 
system development; cell-cell adhesion; cell development; cell differentiation; cell fate 
specification; cellular response to growth factor stimulus; dendritic spine morphogenesis; 
microtubule-based movement; neurogenesis; regulation of neuron projection development; 
neural tube closure; patterning of blood vessels; regulation of excitatory postsynaptic 
membrane potential; positive regulation of synaptic transmission, glutamatergic; synapse 
assembly and maturation; vasculature development
48 regulation of cell migration
176
regulation of cell cycle; cell division; cell proliferation; G1/S transition of mitotic cell cycle; 
mitosis; somatic stem cell maintenance
115
regulation of inflammatory response; response to axon injury; response to DNA damage 
stimulus; response to drug; response to hydrogen peroxide; response to mechanical stimulus; 
response to nutrient levels; response to organic nitrogen; response to organic substance; 
response to stress; response to toxin
545
cell-cell signaling; chromatin modification; GTP catabolic process; intracellular protein kinase 
cascade; intracellular protein transport; MAPK cascade; regulation of gene expression; 
regulation of protein phosphorylation and dephosphorylation; regulation of sequence-specific 
DNA binding transcription factor activity; regulation of transcription from RNA polymerase II 
promoter; regulation of transcription, DNA-dependent; nucleosome assembly; regulation of I-
kappaB kinase/NF-kappaB cascade; regulation of protein ubiquitination; protein folding; protein 
import into nucleus; regulation of catalytic activity; regulation of signal transduction; regulation 
of transcription, DNA-dependent; rRNA processing; signal transduction; translation; transport; 
ubiquitin-dependent protein catabolic process
50 regulation of canonical and non-canonical Wnt receptor signaling pathway
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The analysis of the sequences located in intergenic portions of the DNA in control vs. jj 
identified groups of genes involved in the same biological processes observed in the previous 
analysis.  
36% of genes were involved in signaling pathways (Figure 4-18). 26% of genes controlled 
the cellular differentiation and central nervous system development. Cellular growth and 
proliferation were regulated by 9% of genes, as well as cell death process in which 13% of 
genes were implicated.  
Figure 4-17 B showed in detail the different biological processes.  
 
 
 
 
 
 
Figure 4-18. Gene ontology analysis in control vs. jj.  
Percentage of genes grouped by biological function. Sequences reported are located in intergenic regions of the DNA.  
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Figure 4-19. Gene ontology analysis in control vs. jj. 
Number of genes and description of the biological processes were reported. Sequences reported are located in intergenic regions 
of the DNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NUMBER OF GENES BIOLOGICAL PROCESS
16 regulation of apoptotic process in neuronal and non-neuronal cells
32
aging; cell development; cell (neuron, oligodendrocyte) differentiation; cell fate 
commitment; cell fate determination; cell maturation; central nervous system neuron 
development; generation of neurons; learning or memory; neuron migration; organ 
morphogenesis; regulation of synaptic plasticity
12
G1/S transition of mitotic cell cycle; regulation of cell proliferation; regulation of 
neural precursor cell proliferation; regulation of cell cycle
15
response to drug; response to ethanol; response to organic cyclic compound; 
response to organic nitrogen; response to stress
45
chromatin remodeling; intracellular signal transduction; regulation of sequence-
specific DNA binding transcription factor activity; regulation of transcription from 
RNA polymerase II promoter; regulation of transcription, DNA-dependent; 
regulation of gene expression
5 regulation of Wnt receptor signaling pathway
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4.5 HISTOLOGICAL ANALYSIS 
 
The histological staining, H&E and cresyl-violet were performed both in jj and control, 
at the same age of the ChIP-Seq analysis (P9). The entire brain was processed, allowing to 
obtain the complete picture of the CNS. 
Both stainings revealed a wide damage in jj animals if compared to controls. A 
widespread arrest of the cellular differentiation and a lack of the fibrillary component, with a 
subsequent (apparent) cell density increase was observed.  
 Death due to necrotic/apoptotic processes was also observed, particularly localized in 
specific regions, such as inferior colliculi and some areas of the cerebral cortex, where holes 
are clearly visible.  
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In detail, in the cerebellum of jj animals, the most affected area is the Purkinje cell layer 
in which a general disorganization can be observed (Fig 4-20 A). In particular, the Purkinje 
cells seemed to be organized in more than one single layer, as it was reported in several papers 
that focused on the detailed description of the histological aspects in jj cerebellum 74–76. 
Moreover, the Purkinje cells seemed to be characterized by loss of dendritic arbor, and 
the cell body was not well-defined. 
The external granular layer was characterized by high cell density if compared to the 
control, but the thickness presented no apparent differences. 
The cerebellum arbor vitae, or white matter, revealed the presence of cells with 
meganuclei. 
 
Figure 4-20. View of cerebellum (Cll) slices. 
(A) H&E staining (on the left) and cresyl violet staining (on the right) of P9 jj Cll slice. (B) H&E staining (on the left) and 
cresyl violet staining (on the right) of P9 control Cll slice. Both in A and B a higher magnification of a detail was reported 
(squares). In evidence the altered structure of the Purkinje layer in jj animals. 
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In the frontal cortex of jj animals a very high cell density was noticed (Fig 4-21 A). Cell 
bodies with a not-well developed fibrillary component appeared more compact.   
A remarkable damage seemed to be due to a general atrophy and cell sufferance due to 
death processes and alteration of proliferation. In evidence the destruction of the normal aspect 
of the brain parenchyma with a consistent presence of widespread holes. 
Small darker spots represented sites of microgliosis.  
 
Figure 4-21. View of frontal cerebral cortex (Cx) slices. 
(A) H&E staining (on the left) and cresyl violet staining (on the right) of P9 jj frontal Cx. (B) H&E staining (on the left) and 
cresyl violet staining (on the right) of P9 control frontal Cx slice. Both in A and B a higher magnification of a detail was 
reported. In evidence the high cellular density and the presence of widespread holes in jj Cx. 
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The same high cell density with a consistent reduction of the fibrillary component 
observed in the frontal cortex was also reported in the region of the cerebral cortex located over 
the hippocampus in jj animals if compared to the control pups (Fig 4-22 A). The high cell 
compaction seemed to determine the cortex thickness reduction. The distinction between 
nucleus and cytoplasm was very difficult, thus these cells seemed to be not well-differentiated, 
as well as the fibers. Death process through apoptosis and impairment of cell differentiation 
were noticed. Subpial ectasis and reduced thickness of the subpial white matter were observed. 
 
Figure 4-22. View of cerebral cortex (Cx) over the hippocampus slices. 
(A) H&E staining (on the left) and cresyl violet staining (on the right) of P9 jj Cx over the hippocampus slice. (B) H&E 
staining (on the left) and cresyl violet staining (on the right) of P9 control Cx over the hippocampus slice. Both in A and B a 
higher magnification of a detail was reported. In evidence the high cellular density and thickness reduction due to the not-
well differentiated fibrillary component in jj Cx. 
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The hippocampus of jj rats appeared thinned with very condensed cellular elements (Fig 
4-23 A). Dendrites and the entire fibrillary component seemed not well-defined and generally 
collapsed. Cells seemed to undergo to apoptotic processes that determine a high nuclei 
compaction.  
 
Figure 4-23. View of hippocampus (Hip) slices. 
(A) H&E staining (on the left) and cresyl violet staining (on the right) of P9 jj Hip slice. (B) H&E staining (on the left) and 
cresyl violet staining (on the right) of P9 control Hip slice. Both in A and B a higher magnification of a detail was reported. 
In evidence, the hippocampal structure was extremely thinner with highly condensed cell bodies and collapsed fibrillary 
component. 
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The inferior colliculi of jj animals (Fig 4-24 A) were characterized by a general 
impairment of the parenchyma with widespread holes, particularly concentrated in the central 
area rather than the periphery. The cell morphology was not well-characterized if compared to 
the control one. Megacells in degeneration were detected.  
 
Figure 4-24. View of inferior colliculi (IC) slices. 
(A) H&E staining (on the left) and cresyl violet staining (on the right) of P9 jj IC. (B) H&E staining (on the left) and cresyl 
violet staining (on the right) of P9 control IC slice. Both in A and B a higher magnification of a detail was reported. In 
evidence a general impairment of the parenchyma with widespread holes concentrated in the central area of the jj IC. 
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In the superior colliculi of jj pups (Fig 4-25 A) a higher cell density if compared to control 
was noticed. Neurons seemed to suffer: an altered and not well-designed morphology of the 
cell with no clear difference between nucleus, cytoplasm and the cellular membrane was 
observed. Swollen nuclei and macrocells were detected. Presence of microgliosis. 
 
 
Figure 4-25. View of superior colliculi (SC) slices. 
(A) H&E staining (on the left) and cresyl violet staining (on the right) of P9 jj SC slice. (B) H&E staining (on the left) and 
cresyl violet staining (on the right) of P9 control SC slice. Both in A and B a higher magnification of a detail was reported. In 
evidence not-well designed cell morphology in jj SC. 
 
  BIBLIOGRAPHY 
 
 
69 
 
5 DISCUSSION AND CONCLUSION 
 
 
Epigenetics defines those mechanisms that are directly responsible for the regulation of 
gene expression without changing the DNA sequence, conducting embryogenesis and 
influencing the development of individual’s body and brain during different stages of life 211. 
A deregulation of these complex orchestrated events might also exert negative and diseased 
outcomes. In particular, histone acetylation is responsible for DNA packaging regulation with 
powerful influence in transcriptional activity/silencing; it is also deeply involved in brain 
physiological processes and pathologies 116.  
Common cellular mechanisms impairments were described both in several brain diseases, 
but also in the neurological dysfunction due to high levels of bilirubin. In this disease, the 
activation of complex signaling pathways and the modulation of the expression of a 
considerable number of genes was demonstrated to be directly triggered by bilirubin 
23,79,84,91,97,98,100,106,108–110. Moreover, the heterogeneity of the brain, defined not only in terms of 
cellular composition and interaction but also considering the vulnerability of selected brain 
areas to environmental challenge, was observed also in bilirubin-induced encephalopathy 
23,82,84. 
For these reasons, we decided to explore the involvement of histone acetylation in 
bilirubin-induced encephalopathy using the well-characterized rat model for 
hyperbilirubinemia.  
The screening of the acetyl-histone H3 (lys 14) protein on five brain regions (Cx, Cll, 
Hip, SC, and IC) at three ages after birth (P2, P9, P17) and in adulthood clearly evidenced the 
different capability of each area to respond to the bilirubin insult, despite the same bilirubin 
level measured in (about 5-6nmol/g) 29,30.  
As first, the modulation of the H3K14ac seems to require some time of bilirubin 
challenge, as evidenced by the absence of detectable differences in the H3K14ac levels in all jj 
brain regions at P2. This result could be explained by a correlation with the time of exposure to 
bilirubin or by the fact that the early stage after birth (P2) could be less sensitive to bilirubin 
compared to the other ages. In rodents, the CNS experiences a dormant period immediately 
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after birth 212, possibly making the brain less sensitive to the actions of toxins 23. In agreement, 
the critical period for bilirubin-induced damage was identified around 6-10 days after birth in 
the Gunn rat 28,73,75. Thus, 48 hours of exposure to bilirubin are not enough to exert any effects 
on histone H3 acetylation.  
In the other ages, H3K14ac expression followed an age- and region-dependent course. 
Cll, IC, and Hip reported a significant increase of this protein at P9, while a significant decrease 
was present only in Cll and IC at P17. In adulthood, these brain regions normalized the 
H3K14ac level (vs. ctrl), while Cx showed a significant reduction.  
The upregulation of the H3K14ac in some brain regions at P9, following the increasing 
TSB level (about 13 mg/dL) measured at this age, might suggest the chromatin opening in DNA 
sequences that could be responsible for protection/resistance mechanisms activation. 
Otherwise, the normalization/downregulation of the H3K14ac observed at P17, despite the 
incessant increasing of TSB level (around 15 mg/dL), might be due to the closing of the portions 
of chromatin controlled by this specific epigenetic mechanism in DNA region that regulate 
protection/resistance pathways in place of the activation of other regulatory mechanisms for 
cellular damage and death. Another possible explanation could be linked to the different plasma 
bilirubin/albumin molar ratio (B/A) detected at these four ages and reported in the study 
conducted by Gazzin and colleagues in 2012 30. In this study, the B/A ratio was reported to be 
higher than 1 in jj at P2 and P9, increasing the risk for bilirubin neurotoxicity, while it decreases 
within a safe range (> 0.5) at P17 and in older animals. The trend to reduction was reflected by 
the amount of bilirubin in brain 30. This could explain the normalization of the H3K14ac level 
observed during the maturation of the animal.  
The marked cerebellar hypoplasia is the hallmark of the hyperbilirubinemic animal 
models 30,40,74. Our histological results on P9 cerebellum well agree with previous works 74–76 
showing a marked disorganization of the Purkinje cells still disposed in multilayer rather than 
in a single layer as in controls. As Altman described in his work, one phase of the normal 
cerebellar development is the Purkinje cells maturation, characterized by the alignment of this 
cell type in a monolayer and the dendrites projection towards the molecular layer 213. Our 
findings demonstrated that bilirubin could compromise these two developmental processes, 
probably decelerating/delaying the cellular migration. The disorganized architecture, the 
degeneration of the dendritic arbor, as well as not-well-defined cell bodies, agrees with the 
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observation of an impairment of synaptogenesis showed in Gunn rats by Yamamura 76, and is 
confirmed in the Ugt knock-in mouse 40. Moreover, the injured myelination reported by Brito 
80 and Barateiro 97 could be inferred also in our histological findings that evidenced a relevant 
fibrillary component alteration. Even if other works described a thinning of the molecular layer 
(ML) with lower cellular density at P9, while the external granular layer (EGL) and internal 
granular layer (IGL) started to reduce thickness after this age 76, our staining seemed to show 
higher cellular density without reduction of this layer. An abnormal stratification of the 
cerebellar layers was also confirmed in the P5 Ugt knock-in mouse 40 with a different pattern: 
a thinner external germinal layer and a thicker internal granular layer were observed in mutant 
cerebella. The main differences in the animal models and strains, as well as in the severity of 
the phenotype, could explain the different cerebellar architecture we found, compared to the 
other models. The involvement of this brain structure is finally confirmed in case reports of 
pre-term infants died with kernicterus 80,214, corroborating the symptoms described in clinics 
215.  
Although cerebellum is the most studied brain region using animal models for 
hyperbilirubinemia, also IC, a key part of the auditory pathway, and Hip, principal location of 
the memory functions, were demonstrated to be damaged by bilirubin both in in vivo and ex 
vivo works. Causes of the hearing loss in Gunn rat model, reflecting an auditory pathway 
damage, seemed to be the degeneration of excitatory synaptic terminals in the auditory 
brainstem 216, but also the alteration of calcium-binding protein expression 217. Moreover, 
apoptosis and necrosis 218, as well as synaptic potential inhibition 219,220 and microglial activated 
morphology 221 were reported. In clinical practice, the damage of IC was demonstrated 
observing alterations of the auditory evoked potentials 64,222–225, while the Hip impairment was 
supposed by memory deficits 88,220. Newborn autopsies that reported yellow staining and 
cellular impairment in the hippocampus and inferior colliculi 226 confirmed the clinical reports. 
Our histological results for Hip and IC confirmed the bilirubin-induced impairment described 
in the studies mentioned above. A part a general higher cell density with not-well defined cell 
morphology, in IC widespread holes, symptoms of tissue degeneration, were evidenced, while 
in Hip the general architecture of the layers appeared condensed with scarce development of 
the fibers. 
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Interestingly, Cx, usually considered resistant to bilirubin by clinicians 227, is a double-
edged brain region. In fact, a large number of in vitro 104,108,228–230 and animal model-based 
works reported its sensitivity to bilirubin 23,219,231,232. Our histological images of P9 jj animals 
seemed to confirm the Cx vulnerability to bilirubin insult, displaying a general tissue 
sufferance, highlighting the same cell density increase and relevant reduction of the fibrillary 
component observed in the other regions, and also a widespread riddled aspect. Surprisingly, 
the H3K14ac showed no variations among the three developmental ages taken into 
consideration in my work, despite the higher TSB level, while reporting a significant 
downregulation in older animals, completely not-aligned with the other brain regions, despite 
the TSB was decreased at not-toxic levels. This intriguing result suggests that the neonatal and 
juvenile exposure to high UCB levels may have influences on epigenetic mechanisms also in 
aging. The absolute novelty of this work was determined by the systematic and complete 
evaluation of the biomolecular mechanisms of bilirubin toxicity, introducing the possible 
regulation of gene expression by histone acetylation, comparing different brain regions and 
different ages. 
Despite the whole panel of histological data should be assessed in the other post natal 
ages, these findings suggest that bilirubin interferes with cell proliferation and blocks cell 
differentiation, maturation and/or migration. The ChIP-Seq results seemed to be in agreement 
with the histological findings and with the overall knowledge of the CNS development present 
in literature. Our analysis revealed that in P9 jj cerebellum very few sequences (about 200) 
seemed to be linked to H3K14ac, with the highest percentage of sequences (87%) located in 
the intergenic region of the DNA (LINE and satellite) and a lower percentage of sequences 
located on the promoter-TSS, intron and exon regions of the DNA. On the other hand, a very 
high number of sequences (over 3000) seemed to be present only in controls, thus suggesting 
that a very high percentage of genes controlled by H3K14ac was silenced in jj animals. 
Generally speaking, a part the genes that regulate physiological signaling pathways, the genes 
grouped by the gene ontology analysis seemed to be involved in the regulation of development 
and differentiation, proliferation, migration and apoptosis pathways. The fact that in jj animals 
these processes seemed to be inactive at this specific age revealed that the normal modeling of 
the cerebellum could be affected by bilirubin. Furthermore, the detection of a very high 
percentage of intergenic DNA compared to the coding-DNA in jj may be considered peculiar. 
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In fact, despite the intergenic DNA has been classified as “junk” for many years, recently its 
role has been reconsidered. These repetitive elements, including satellite DNA and 
retrotransposons, such as LINE, seemed to be part of the heterochromatin and essential for 
chromosome stability and gene expression regulation 233–235. Again, few studies reported their 
involvement in some diseases, hypothesizing the heterochromatin destabilization with 
consequent inappropriate transcription 236,237, as well as their linking to histone modification 
and DNA methylation 238–240. Currently, the understanding of these DNA sequences in diseases 
is still incomplete, especially because ChIP-seq, a very powerful tool to investigate the 
epigenetic regulation of genome, is limited to the investigations that are already known 241,242. 
New technologies able to analyze repeat sequences might better understanding this subject. 
In conclusion, this work reported for the first time the involvement of histone acetylation 
in the brain of hyperbilirubinemic animals with a strong regulation of the gene expression. The 
complete panel of genes we obtained seemed to well-correlate with the bilirubin-induced 
damage that evidenced the development impairment. All together, these results represented a 
relevant contribution to better understand the bio-molecular mechanisms that cause bilirubin 
toxicity, but also might be important to consider new pre-clinical therapies in kernicterus, 
testing the neuroprotective properties of drugs able to regulate the histone acetylation.  
In future, we plan to complete this project by: 
- Completing the panel of the temporal trend of the bilirubin effect on the different 
brain regions by the histological staining of P2, P17, and older brains. This may 
contribute to improving our knowledge of this pathology.   
- Analyzing a selected list of genes obtained by the ChIP-seq analysis, by RT-qPCR in 
all the brain regions at all the ages considered in this work in order to have more 
quantitative information. This could be useful to introduce new hypothesis relative to 
the influence of biomolecular mechanisms on the hyperbilirubinemic phenotype. 
- Publishing a peer-review paper that will be of a great novelty for the study of the 
biomolecular mechanisms in kernicterus, introducing epigenetic and the clear 
bilirubin influence on CNS development.  
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